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Abstract 
 
Introduction: Protein aggregations are pathological hallmarks of motor neuron disease (MND) and have 
been shown to cause activation of endoplasmic reticulum (ER) stress sensors. ER stress-induced pathways 
can lead to multiple outcomes including degradation of protein aggregates or cell death. Using RNAseq data 
from C9ORF72 mutants as a starting point we sought to investigate the relationship between ER stress and 
protein aggregation in induced pluripotent stem cell (iPSC) derived spinal motor neurons (sMNs).  
 
Methods: iPSCs were differentiated into sMNs from subjects with the C9ORF72 repeat expansion, 
TARDBPG298S and TARDBPM337V mutations with CRISPR/Cas9 gene-corrected controls. Previously obtained 
RNAseq data from C9ORF72 mutants was subject to GO analysis with candidates validated by qPCR. ER 
stress pathways were assessed by PCR for XBP1 splicing and Western blotting for ATF6 and PERK in 
untreated and tunicamycin-treated sMNs at three weeks post platedown. A survival assay following 
tunicamycin treatment was performed on three-week-old sMNs. TDP-43 pathology has been characterised 
by Western blotting and immunocytochemistry (ICC) and dipeptide repeat (DPR) proteins by ICC.  
 
Results: RNAseq data from C9ORF72 mutant sMNs was enriched for genes involved in protein homeostasis. 
HSPB8, a protein implicated in clearing TDP-43 aggregations, was confirmed to be upregulated in C9ORF72 
mutant sMNs. TDP-43 pathology, however, was not present in these cells. DPR protein aggregates are 
present in C9ORF72 mutants at this time but there was no evidence of ER stress activation. Treatment of 
C9ORF72 mutants with tunicamycin, however, activates an ER stress response determined by increased 
PERK and ATF6 splicing to an extent greater than that seen in controls. Treatment with tunicamycin was not 
associated with a survival deficit. For comparison, TARDBP mutants were investigated which display TDP-
43 pathology and ER stress evidenced by ATF6 splicing.  
 
Conclusion: There is early evidence for differences in ER stress in both C9ORF72 and TARDBP mutants. 
DPR proteins may disrupt cellular protein homeostasis in a manner distinct from that of TDP-43 pathology 
and are an early feature of disease in C9ORF72 mutants. These findings have implications for understanding 
the pathogenesis of MND and drug screening.  
 
Additional Chapter: In the absence of a gene-corrected control for TARDBPM337V a strategy for CRISPR/Cas9 
mediated gene-correction of the M337V mutation is presented. 
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Lay Summary 
 
Motor neuron disease (MND) is a disorder in which the cells that allow us to move muscle (motor 
neurons) die. Understanding why these motor neurons die may help us to treat MND. 
One of the common features of MND is the presence of clumps of protein within motor neurons. 
In this study, we look at MND caused by two errors in DNA which can lead to the formation of 
such protein clumps. These two errors affect two different bits of DNA – one called C9ORF72 and 
the other TARDBP. Both errors lead to clumping of a protein called TDP-43. The C9ORF72 error 
also results in another type of protein clump containing dipeptide repeat (DPR) proteins. Our cells 
can only work if they contain the right amount of protein and this balance is maintained by a part 
of the cell called the endoplasmic reticulum (ER). Too much protein results in ER stress pathway 
activation. 
To study the effect of these DNA errors on protein clumping and ER stress, cells from patients 
with the DNA errors were converted to motor neurons grown in dishes in the laboratory.  
When levels of ER stress in three-week-old motor neurons from patients with MND due to the 
C9ORF72 error were compared to those of healthy people no difference was observed. These cells 
contained the DPR protein clumps but not the TDP-43 clumps. When these cells were treated with 
the drug tunicamycin to cause ER stress they reacted more strongly than normal cells. This 
suggests that although they do not show ER stress under normal conditions they do have a 
vulnerability to stress. To see if such stress might impact the lifespan of motor neurons we treated 
cells with the C9ORF72 error with tunicamycin but there was no difference in survival.  
In comparison, the cells with the TARDBP DNA error did show TDP-43 aggregation at three weeks 
and evidence of an active ER stress response. This is in keeping with the idea that TDP-43 protein 
clumps can activate ER stress pathways that may lead to motor neuron death in MND.  
Further investigation is required, but these findings are important because they help us to link the 
protein clumps observed in patients with MND to a possible mechanism by which motor neurons 
may die. It also suggests that even though TDP-43 protein clumps are present in most cases of 
MND they may play different roles in patients depending on the DNA error that caused the MND. 
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Chapter 1: Background 
 
What is motor neuron disease? 
 
The nomenclature surrounding motor neuron disease is inconsistent and complicated. The 
term motor neuron diseases (plural) is used to describe a family of conditions in which the 
clinical features of disease arise primarily from the degeneration of motor neurons (MNs) 
These disorders include spinal muscular atrophy (SMA), hereditary spastic paraplegia (HSP), 
post-irradiation lumbosacral radiculopathy, motor neuron diseases of a known infective or 
metabolic aetiology and motor neuron disease (MND) itself. MND is further divided into 
different clinical syndromes depending on the location of affected motor neurons (Table 1). 
Upper motor neurons (UMNs) are neurons situated in the brain or brainstem which project 
axons to lower motor neurons (LMNs). The cell bodies of LMNs lie within the brainstem or 
anterior horn of the spinal cord and project axons to muscle. 
 
Motor Neurons Affected Syndrome Name 
LMNs Progressive muscular atrophy (PMA) 
UMNs Primary lateral sclerosis (PLS) 
LMNs and UMNs 
throughout the body 
Amyotrophic lateral sclerosis (ALS) 
LMNs and UMNs of the 
bulbar region 
Progressive bulbar palsy (PBP) 
Table 1: MND subtypes by MN group affected 
 
The most common MND syndrome is amyotrophic lateral sclerosis (ALS). In the United 
Kingdom, these terms are often used interchangeably though a difference exists. In the United 
States, ALS and MND are truly synonymous. Whether these different clinical syndromes 
reflect different underlying disease processes remains a question for debate. The clinical 
syndrome of individuals within families with familial MND (fMND) often varies though 
suggesting a common predisposition to MND which is modified by factors within the affected 
individual to determine the specific syndrome that develops (Mulder et al. 1986; Siddique and 
Pericak-Vance 1989). 
 
The aetiology of MND is complex and, as for most other diseases, it is often stated that it is 
likely both genetic and environmental factors interact to cause disease. Various environmental 
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factors have been suggested over the years including viral and heavy metal based aetiologies 
but the evidence has never given prominence to any one theory (Ingre et al. 2015). Arguably 
more progress has been made in dissecting the genetic contributors to MND and an ever-
growing number of genes are now associated with the disease. Some mutations identified 
appear able to cause MND with Mendelian inheritance and high penetrance, others act as risk 
factors or disease-modifiers (Leblond et al. 2014). Evidence of oligogenic MND (in which more 
than one MND-associated gene has been found to carry mutations in an individual with 
MND) is also increasing with a recent systematic review and meta-analysis suggesting as 
many as 0.4% of cases are oligogenic – far higher than would be expected by chance (Zou et 
al. 2017). This percentage will only increase as more mutations are associated with MND. This 
is in keeping with a population level study that used statistical modelling techniques to 
suggest the development of MND is a multistep process (Al-Chalabi et al. 2014). MND-
associated with a hexanucleotide repeat expansion (HRE) in C9ORF72 (termed C9-MND) is 
likely to provide an excellent insight into the multistep nature of this process given that the 
C9ORF72 HRE has been associated with a number of neurodegenerative diseases including 
MND (DeJesus-Hernandez et al. 2011; Majounie et al. 2011), frontotemporal dementia (FTD)  
and less frequently in Huntington disease phenocopies (Hensman et al. 2014; Kostic et al. 
2014); Alzheimer’s disease (Majounie et al. 2012; Kwon et al. 2013) and  others. 
 
The increasing number of genetic mutations associated with MND has given rise to a plethora 
of model systems which have been used to study neurodegenerative mechanisms. Two 
affected genes have been studied by the Chandran lab – C9ORF72 and TARDBP. The C9ORF72 
HRE is the most common cause of MND in European populations where it accounts for 
around 33.7% of familial and 5.1% of sporadic cases at the latest count (Zou et al. 2017). 
Mutations in TARDBP also potentially allow inference about a large proportion of MND cases 
because, although mutations in TARDBP are much rarer, the protein product, TDP-43, is a 
major component of inclusion bodies in most MND cases (Neumann et al. 2006). The notable 
exceptions are MND caused by mutations in SOD1 (Mackenzie et al. 2007) and FUS (Vance et 
al. 2009). 
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C9-MND pathology is the focus of this work and endoplasmic reticulum stress and the 
unfolded protein response have been investigated in an attempt to understand the 
contribution of proteinopathy to MND with data from TARDBP mutant lines included for 
comparison at points.  
 
Since association of the C9ORF72 HRE with MND and FTD (DeJesus-Hernandez et al. 2011; 
Majounie et al. 2011) three main hypotheses have arisen seeking to explain how the HRE 
causes neurodegeneration: loss of function of endogenous C9ORF72; neurodegeneration as a 
result of toxic RNA species and toxicity resulting from dipeptide repeat (DPR) proteins. These 
processes are complex and have been the subject of recent reviews but some of the key 
findings and issues are described here. 
 
A loss of function neurodegenerative mechanism relies on the observation of decreased 
expression or function of the C9ORF72 protein. The function of C9ORF72 is still poorly 
understood. In C9ORF72 orthologs in Caenorhabditis elegans and zebrafish, F18A1.6 and 
zC9orf72 respectively, reducing ortholog expression resulted in motor phenotypes (Ciura et 
al. 2013; Therrien et al. 2013). In zebrafish, this deficit was rescued by expression of human 
C9ORF72 (Ciura et al. 2013). Neurodegeneration following C9orf72 knockdown has not, 
however, been replicated in rodent models (Lagier-Tourenne et al. 2013; Wen et al. 2014; 
Koppers et al. 2015). Work on human tissue has lent little clarity to the debate. The 
transcription of C9ORF72 results in three different pre-mRNAs. In variants 1 and 3 the HRE 
lies within an intronic region whereas in variant 2 the HRE exists within the promoter. 
Different studies on post-mortem tissue and stem cell models have suggested that all 
transcript levels are decreased or that transcripts are differentially affected – reviewed by 
Gitler et al. (Gitler and Tsuiji 2016). A key argument against a loss of function mechanism of 
neurodegeneration comes from the observation that individuals homozygous for the mutant 
allele do not develop as severe a disease as might be expected given the impairment of 
endogenous C9ORF72 function (Fratta et al. 2013). Furthermore, mutations have not yet been 
identified with exons of C9ORF72 which might be expected to cause pathology if C9ORF72 is 
required for normal functioning of the nervous system. 
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The second key hypothesis suggests that RNA foci which accumulate in the nuclei and 
cytoplasm of cells from patients with the C9ORF72 HRE cause neurodegenerative disease 
(DeJesus-Hernandez et al. 2011; Majounie et al. 2011). In other diseases such as myotonic 
dystrophy type 1 RNA foci have been shown to result in sequestration of vital RNA processing 
machinery leading to toxicity (Echeverria and Cooper 2012). Similarly, many independent 
studies have shown that RNA foci in C9ORF72 sequester a number of  RNA binding proteins 
such as Pur-alpha and hnRNPA1. In a C9ORF72 HRE iPSC model treatment with antisense 
oligonucleotides (ASOs) targeting both within and out with the HRE sequence rescued a 
glutamate-induced excitotoxicity phenotype which it was claimed demonstrated an RNA foci-
mediated toxic gain of function mechanism (Donnelly et al. 2013). The effect of ASO treatment 
on the production of DPRs though was not assessed and could confound interpretation of 
those results.  Evidence from other sources argues against the role of a toxic RNA as a disease 
driver. The presence of RNA foci throughout a number of cell types in human MND and FTD 
not prone to neurodegeneration (Dejesus‑hernandez et al. 2017) along with their presence in 
animal models such as the BAC transgenic mouse described earlier (Peters et al. 2015) makes 
it unlikely they alone are sufficient to cause neurodegeneration despite their close association 
with the C9ORF72 HRE.  
 
Finally, DPR proteinopathy is considered. Unconventional non-ATG mediated translation of 
the C9ORF72 HRE in all six reading frames leads to the production of six different DPR 
proteins: glycine-proline (GP), glycine-alanine (GA), glycine-arginine (GR), proline-glycine 
(PG), proline-arginine (PR) and proline-alanine (PA). In the absence of RNA foci, evidence has 
been obtained that DPR proteins alone are capable of inducing neurodegenerative 
phenotypes. In one study poly-GA expression in mice caused neurodegeneration and 
behavioural abnormalities along with deficits in nucleocytoplasmic transport (Zhang et al. 
2016). While this finding supports the idea that DPR proteins may drive neurodegeneration it 
leaves a number of questions unanswered relating to the distribution of DPR proteins in 
human disease and also in the lack of co-existing TDP-43 pathology which is present in almost 
all cases of MND and FTD associated with the C9ORF72 HRE. Again, DPR pathology in 
human subjects correlates poorly with neurodegeneration (MacKenzie et al. 2013) and DPRs 
are rarely seen in sMNs which are predominantly affected in ALS (Gomez-Deza et al. 2015). 
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Motor neuron disease as a proteinopathy 
 
The association of TARDBP mutations with the major component of protein aggregates in 
MND has supported the hypothesis of MND as a proteinopathy. The mechanisms by which 
cells maintain proteostasis are briefly reviewed focusing on those aspects relevant to the 
experimental data. Evidence suggesting endoplasmic reticulum (ER) stress and the unfolded 




Protein folding describes the process by which proteins acquire a three-dimensional structure. 
It is noteworthy that not all proteins are folded. Alpha-synuclein, best known for its role in 
Parkinson’s disease, is an intrinsically disordered protein which, in the central nervous system 
(CNS) of humans and other species, exists as a monomeric form with no consistent 3D 
structure (Fauvet et al. 2012).  
 
The manner in which proteins fold is complex, described in a review article as a ‘stochastic 
search’ rather than ‘mandatory steps’ (Dobson 2003). Protein folding is subject to both intrinsic 
and extrinsic factors. Intrinsic factors include the primary, secondary and tertiary structures 
of a protein. In addition to quaternary protein structure are other environmental factors that 
affect protein folding. One such physiologically relevant environmental factor is a crowded 
molecular environment (Zhou 2013). Within the cell, different proteins are folded within 
different compartments including the cytoplasm, mitochondria and endoplasmic reticulum 
(Dobson and Ellis 1998). 
 
A group of proteins called chaperones also serve important roles in the protein folding 
pathway. Chaperones improve the efficiency of protein folding by reducing the likelihood of 
competing reactions rather than acting as catalysts (Dobson 2003).  In addition to chaperones, 
proteins with a catalytic role in protein folding have been described. Of particular note here 
with respect to MND are the protein disulphide isomerases (PDIs) which are involved in the 
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establishment of disulphide bonds (Wilkinson and Gilbert 2004). Dysfunction of both these 
classes of molecule has been implicated in the pathophysiology of MND.  
 
If normal protein folding cannot be achieved, for example, because a protein is destabilised 
through mutation, an unfolded protein response (UPR) is launched by three stress sensors 
that reside in the membrane of the endoplasmic reticulum (ER) – IRE1, PERK and ATF6 
(Figure 1). 
 
Inositol Requiring Enzyme 1 (IRE1) 
 
On ER stress, dissociation of glucose-related protein 78kDa (GRP78, also commonly referred 
to as BiP) from IRE1 activates RNase activity that results in excision of a 26bp unconventional 
intron leading to a truncated X-box binding protein 1 (XBP1) transcript and XBP1 protein. The 
truncated XBP1 transcript encodes a stable transcription factor which is capable of binding to 
the ER stress response element (ERSE) (Yoshida et al. 2001). The consequences of activation of 
the ERSE are described below. 
 
Protein kinase RNA-like endoplasmic reticulum kinase 
 
On ER stress, protein kinase RNA-like endoplasmic reticulum kinase (PERK) undergoes 
oligomerization and autophosphorylation (Bertolotti et al. 2000). Phosphorylation of PERK 
leads to phosphorylation of its downstream target eukaryotic translation initiation factor 2 
alpha (eIF2α) (Harding et al. 1999). Phosphorylation of eIF2α causes almost global 
translational inhibition (Harding et al. 2000). One notably spared transcript is that of 
activating transcription factor 4 (ATF4) which is itself capable of inducing the transcription 
factor CCAAT-enhancer-binding protein homologous protein (CHOP) (Harding et al. 2000). 
The downstream effects of CHOP upregulation are broad and include induction of apoptosis 
and increasing reactive oxygen species (ROS) generation (Nishitoh 2012). 
The response of PERK to ER stress is subject to a negative feedback loop involving growth 
arrest and DNA damage gene 34 (GADD34)  (Novoa et al. 2001). 
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ATF6 
 
ATF6 is inserted into the ER membrane following its synthesis. Under ER stress GRP78 
dissociates from ATF6 exposing two Golgi localisation sequences resulting in translocation of 
ATF6 to the Golgi apparatus (Shen et al. 2002). In the Golgi apparatus, ATF6 is cleaved and 
this cleaved fraction translocates to the nucleus where it functions as a transcription factor. 
Promotors containing a cis-acting ERSE are activated leading to increased expression of a 
number of chaperone proteins (Yoshida et al. 1998). Upregulated targets include GRP78, 
CHOP and XBP1 (Yoshida et al. 2000). 
 
 
Figure 1: Simplified pathways activated by ER stress sensors PERK, IRE1 and ATF6 from 
(Celli and Tsolis 2014). Abbreviations: RIDD – IRE1 dependent decay, S1P – site 1 protease, 
S2P – site 2 protease, ERAD – endoplasmic reticulum-associated degradation. Processes 
following the activation of the three ER stress sensors are described in the text. 
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The unfolded protein response and endoplasmic reticulum stress in MND 
 
Post-mortem examination the anterior horn cells of patients with MND has revealed 
abnormalities in the ER (Oyanagi et al. 2008). Pathology has also been reported to affect the 
Golgi apparatus – another key organelle involved in protein homeostasis (Gonatas et al. 1992). 
In SOD1 mutant mouse models of MND Golgi fragmentation has been shown to occur prior 
to muscle denervation supporting a dying-forwards hypothesis in which soma degeneration 
precedes that of the axon (van Dis et al. 2014). 
 
Of the two major groups of protein aggregates relevant to C9-MND, TDP-43 and the DPR 
proteins, the evidence favours a TDP-43 based pathology in humans. Evidence for and against 
a DPR proteinopathy has been presented in C9-MND. Here, it is noted that TDP-43 pathology 
is better spatially correlated with neurodegeneration in the human nervous system as 
opposed to DPR proteins which occur throughout the CNS in a variety of unaffected cells 
(MacKenzie et al. 2013; Davidson et al. 2014). 
 
In cases of MND and FTD TDP-43 pathology has been described in several forms: cytoplasmic 
aggregation, nuclear clearance, truncated C-terminal fragments and hyperphosphorylated 
(Neumann et al. 2006). Evidence has recently been provided that TDP-43 pathology may be 
made worse by ER stress through inhibition of non-sense mediated RNA decay (Li et al. 2016). 
PERK appears the main ER stress sensor required for non-sense mediated RNA decay and has 
been shown to be upregulated in MND post-mortem tissue.  
 
It should also be noted despite the common nature of inclusion bodies in MND there is 
evidence that TARDBP mutations can cause MND in the absence of TDP-43 aggregation or 
nuclear clearance though such cases are rare (Arnold et al. 2013) 
 
The role of stem cell models 
 
The ability to generate cellular models from human subjects with MND has granted new 
opportunities to investigate neurodegeneration in human biochemical systems. Several 
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methods now exist by which somatic human cells can be biopsied and converted to a cell type 
of interest. The two main strategies are: 
 iPSC generation followed by differentiation 
 direct reprogramming  
 
Human cellular models of MND provide a mechanism by which genetic configurations that 
cause human disease can be studied in their entirety. This is in contrast to animal models in 
which gene mutations or mutant proteins are introduced recapitulating only specific parts of 
pathology though this of course in cases is capable of producing applicable phenotypes. The 
ability to study the interaction between many risk loci is likely to be particularly important in 
complex genetic diseases like MND. The same phenomenon allows dissection of 
pathophysiological processes underlying sporadic disease. Reprogramming technologies 
have proved particularly valuable in MND because of the practical issues obtaining neural 
tissue biopsies in life. Studies were, as a result, previously confined to end-stage pathology 
save in rare occurrences where the subjects death occurred early in the disease course in a 
manner not directly dependent on the disease. For this reason, the ability to examine the 
progression of pathology, as is possible in animal models, in human disease is invaluable. 
Components of these pathways can then be manipulated increasing our mechanistic 
understanding of the disease process.  
 
Cellular models are not without limitations. While it is desirable that the base sequence be 
conserved though out the reprogramming process and subsequent passaging, sporadic 
mutations can occur (Ji et al. 2012). Concerns also arise regarding the conservation of 
epigenetic memory (Vaskova et al. 2013). For example, protective and degenerative roles for 
hypermethylation of the mutant C9ORF72 allele have been proposed. Evidence of a protective 
effect of hypermethylation includes the observation that the number of RNA foci decrease on 
hypermethylation and increased vulnerability to autophagy and oxidative stress is abated 
(Liu et al. 2014). These potentially neuroprotective effects have also been studied in human 
patients (McMillan et al. 2015; Russ et al. 2015). It has also been suggested that 
hypermethylation in this area might lead to transcriptional silencing and loss-of-function 
neurodegeneration but strong evidence for this is currently lacking (Haeusler et al. 2016). 
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There is evidence that the specific methylation status of patients with C9ORF72 HRE-
associated disease is preserved following the reprogramming of C9-MND patient fibroblasts 
(Esanov et al. 2016). It is also important to remember that MND usually occurs after 50 years 
of age and the relevance of studying cells which are usually just weeks (even days) old is to 
be considered. There is excellent evidence though now that with longitudinal neuronal culture 
more mature cellular phenotypes are observed. A clear example of this comes from the field 
of Alzheimer’s disease in which the abundance of different tau isoforms has been observed to 
vary in cellular models from developmental signatures to that seen in adult humans over a 
year in culture (Sposito et al. 2015). 
 
Variability among different cell lines is considerable and has been widely reported. A review 
(Soldner and Jaenisch 2012) suggests three possible levels at which is variability could arise: 
1. Reprogramming 
2. Differentiation 
3. Genetic background 
 
In vivo differentiation protocols often produce a mixed cell population. In the spinal motor 
neuron (sMN) differentiation protocol used here approximately 60% of cells express motor 
neuron markers. The neuronal population is said to account for 90% of cells though we believe 
this closer to 100% at one week with a slowly increasing non-neuronal population as time in 
culture increases. A protocol generating a completely pure culture of sMNs would be valuable 
particularly for biochemical studies seeking to study this cell type specifically. Increasing the 
efficiency of differentiation protocols is complex and costly but other alternatives exist to 
enrich cultures of cell types of interest. These usually require additional genomic 
manipulation though such as the integration of antibiotic resistance genes for selection or 
reporters for processes like fluorescence-activated cell sorting (FACS). We have chosen not to 
take such measures in an effort to preserve the genome as much as possible. Processes like 
FACS are also more amenable to some cell types than others. FACS of MNs would axotomise 
cells and would be associated with a low survival though it is possible. 
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Differences in genetic background confound analysis in many disease models. Advances in 
gene–editing have allowed the creation of isogenic control lines in which mutations can be 
removed using the CRISPR/Cas9 system. This allows pairwise comparisons in which the only 
variables are the mutation (either present or corrected) and the gene-editing process. At a 
recent meeting of the Dementias Platform UK Stem Cell Network, it was suggested that 
mutant lines should be subject to sham correction. This would involve mock transfection, low-
density platedown, clonal selection, screening and expansion. Such controls have not been 
used here though they may prove valuable in the future particularly following identification 
of seemingly pathological phenotypes in gene-corrected lines which are described later. 
 
iPSC model systems have been able to recapitulate a number of aspects of C9ORF72 
pathology. RNA foci have been demonstrated in iPSC-derived motor neurons from C9-MND 
patients allowing mechanistic dissection of their protein binding partners (O’Rourke et al. 
2013). The contribution of RNA foci to nucleocytoplasmic shuttling deficits has been reported 
and rescued with ASO treatment (Donnelly et al. 2014). Nucleolar and ER stress have been 
identified in a paper detailing the effects the DNA and RNA structures formed as a result of 
the C9ORF72 HRE (Haeusler et al. 2014). Of particular relevance to this work, ER function has 
been investigated with evidence of calcium dysregulation in the ER and stress granule 
formation (Dafinca et al. 2016). The power of these models to dissect human biochemical 
pathways leading to a mechanistic understanding of C9-MND is immense and the use of such 
systems is only likely to increase with time. 
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Aims 
 
The aim of this project was to validate RNA sequencing candidates involved in protein 
homeostasis and investigate the nature of the unfolded protein response in C9ORF72 mutant 




Prediction 1) Motor neurons derived from subjects with motor neuron disease will exhibit 
activation of the unfolded protein response which will decrease survival. 
 
Prediction 2) The presence of an activated unfolded protein response will correlate with TDP-
43 and DPR protein pathology. 
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Chemicals and Kits 
Material Company Catalogue Number Details 








Bioline BIO-41025  
Alexa Fluor® Dyes ThermoFisher 
Scientific 











GE RPN2235  
Anti-ATF6 Novus Biologicals 70B1413 Mouse, IgG1, 
Unconjugated, WB 
@ 1:1,000 
Anti-Calnexin Cell Signal C5C9 Rabbit, Polyclonal, 
Unconjugated, WB 
@ 1:10,000 
Anti-ChAT Merck Millipore Ab144P Goat, Polyclonal, 
Unconjugated, ICC 
@1:100 
Anti-GAPDH Merck CB1001 Mouse, IgG1, 
Unconjugated, WB 
@ 1:10,000 
Anti-GFAP Sigma C9205 Mouse, IgG1, Cy3 
conjugated ICC @ 
1:1,000  
Anti-ISLET1/2 DSHB 39.4D5 Mouse, IgG2b, 
Unconjugated, ICC 
@ 1:50 
Anti-MAP2 Sigma M9942 Mouse, IgG1, 
Unconjugated, ICC 
@ 1:500 
Anti-TARDBP ProteinTech 12893-1-AP Rabbit, Polyclonal, 
Unconjugated, WB 
@ 1:1,000 
Anti-TDP43 Abnova H00023435 Mouse, IgG1, 
Unconjugated, ICC 
@ 1:200 
Anti-Tau Dako A0024 Rabbit, 
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Ascorbic Acid Sigma A4403  
B27 Life Technologies 17504044  




Sigma DN25   
Bromophenol blue Sigma B0126  
Bovine Albumin 






Calcein AM ThermoFisher 
Scientific 
C1430  
CHIR99021 Tocris 4423 3mM in DMSO 
10mg in 7.16mL 
DMSO 






SIGMA D9542-10MG 10mg/mL in water 
DAPT Tocris 2634 10mM stock 
DMSO Sigma D2438-50ML  
Earl’s Balanced Salt 
Solution 
Life Technologies 24010043  
Ethanol, Absolute ThermoFisher 
Scientific 
BP2818500  
FDU Sigma F0503 See * below 
FGF2 Peprotech 450-33 20μg/mL in 0.1% 
BSA in DPBS 
Fibronectin Sigma F2006 1mg/mL in cold 
PBS 
Leave in the 




FluroSave™ Reagent Calbiochem 345789-20ML  
GDNF Tocris 212-GD 10μg/mL in 0.1% 
BSA 




24594 Referred to 
colloquially as 
Coomassie 
Orange G Sigma O3756 PCR loading gel 
GelRed™ Nucleic 
Acid Gel Stain 
Biotium 41003  
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Glycine Sigma G8898-1KG  
IGF-1 Peprotech AF100-11 20μg/mL in 0.1% 
BSA in DPBS 
1mg in 50mL 0.1% 
BSA in DPBS 
(aliquot in 5mL 
and store at -80°C) 
Immersion Oil 
Immersol 518 F 
fluorescence free, 
oiler 20 ml 
 
Zeiss 444960-0000-000  
Laminin Sigma L2020  
LDN193189 Stratech Scientific S2618 100μM Aliquots in 
DMSO 
50μL of 10mM 




Sigma G5888 25mM 
Matrigel® Corning 354230 1:2 in cold 
Advanced 
DMEM/F12 
Thaw in fridge for 
1 hour 
10mL MG in 10mL 
cold Advanced 
DMEM/F12 
1mL aliquots (will 










MgCl2 Sigma M8266  
N-2 Supplement ThermoFisher 
Scientific 
17502048  
Non-flat dry milk 
powder 





Normal Goat Serum Vector Laboratories S100  
Nuclease-Free Water Ambion AM9937  
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PBS, pH 7.4 ThermoFisher 
Scientific 
10010023  
PFA (16%) Agar Scientific R1026  
Phosphatase 
Inhibitor 
Roche 04906837  
Phosphate Buffered 






Pierce™ BCA Protein 
Assay Kit 
ThermoScientific 23225 Reaction volume 
reduced from 2ml 
to 1ml. Sample 
volume reduced 
from 100μL and 
50μL. 
Polyornithine Sigma P4957  








NEB M0491S  
Q5® High-Fidelity 2x 
Master Mix  
NEB M0492S  
Retinoic acid (RA) 
all-trans 
Sigma R2625 1mM in ethanol 
Stock at 100mM - 
dilute 100μL in 








RNeasy Mini Kit QIAGEN 74106  
SAG Merck 566660 1mM in H2O 
1mg in 1.67mL 
embryo transfer 
water 
SB431542 Tocris 1614 10mM in DMSO 




SIGMA L377-100MG  
Sodium azide Merck S2002  
Sodium chloride Thermofisher 
Scientific 
S/3160/60  
Sodium deoxycholate Sigma D6750  
TAE Buffer In-house NA  
TBS Ultra Pure VWR Life Sciences K859-100  
Thiourea Sigma T8656-100MG  
TriDye™ 100bp 
DNA Ladder 
NEB N32715  
Triton™ X100 Sigma 9002931  
Trizma® base Sigma T1503-1KG  
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Trypan Blue Sigma T8154-100ML  
Trypsin (0.25%, 
phenol red) 
Life Technologies 12634028  
Tunicamycin from 
Streptomyces sp. 
Sigma T7765 Made to 1mg/mL 
in DMSO 
TWEEN20 Aldrich  27,434-8  
UltraPure™ 0.5M 
EDTA, pH 8.0 
Life Technologies 155775020  
Urea Sigma U0631  
Uridine Sigma U3003 See * below 
Y-27632 (Rock 
Inhibitor) 
R&D Systems 1254 10mM in DMSO 
10mg in 3.125mL 
DMSO 
Wizard® SV Genomic 
DNA Purification 
System 
Promega A2361  
Table 2: Table detailing chemicals and kits used for experiments.  
 
*Preparation of Uridine/FDU aliquots. Uridine and FDU were resuspended separately in H2O 
at 20mM then mixed at a ratio of 1:1 such that each component had a final concentration of 
10mM. Small aliquots were prepared to avoid repeated freeze-thaw. 
 
Software 
 ImageJ, Version 1.51h 
 RStudio, Version 1.0.136  
 GraphPad Prism 7 
 SnapGene® Viewer, Version 3.14 
 Primer3, http://primer3.ut.ee/  
 GitHub, https://github.com/ 
 CRISPR Design, http://crispr.mit.edu/  
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Methods 
 
The generation of gene-corrected induced pluripotent stem cells for the study of motor 
neuron disease 
 
Previously generated induced-pluripotent stem cell (iPSC) lines (Table 3) derived from 
patients with MND harbouring C9ORF72 hexanucleotide repeat expansion (HRE) (C9-MND) 






Sex Age at 
Biopsy 
Diagnosis 
Con 1  SeV (non-
integrating) 
Edinburgh - - None (Family 
history of 
psychiatric disease) 
Con 2  Retroviral 
(integrating) 
Edinburgh F 40 None 
C9-1  SeV (non-
integrating) 
Cambridge F 39 ALS 
C9-2  Retroviral 
(integrating) 
Cambridge M 67 ALS 
C9-3  Retroviral 
(integrating) 
Cambridge M 58 ALS 
G298S   Retroviral 
(integrating) 
Cambridge - - ALS 
M337V Episomal (non-
integrating) 
Edinburgh - - ALS 
Table 3: Table showing iPSC lines used with reprogramming method, site and selected 
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The C9ORF72 HRE was excised using two guide RNAs (gRNAs) flanking either side of the 
G4C2 repeats. Double-stranded DNA breaks caused by the gRNAs in the absence of a repair 
template undergo non-homologous end joining (NHEJ). Guide RNAs can bind to both 
wildtype (WT) (containing 2-30 hexanucleotide repeats) and mutant (>30 hexanucleotide 
repeats) alleles. 
 
Figure 2: Diagram showing gRNA targeting sites flanking G4C2 repeats on WT and mutant 
alleles. Diagram created by Dr B. T Selvaraj. 
 
If both gRNAs successfully target a single allele, NHEJ may occur excluding the G4C2 
expansion. This process can result in three outcomes: 
1. Cells in which the G4C2 repeats are not removed because double-stranded DNA breaks 
were not introduced by both gRNAs. 
2. Cells heterozygous for the G4C2 repeats in which one allele only is successfully targeted 
by both gRNAs with NHEJ. 
3. Homozygous deletion of G4C2 repeats in which both alleles have been successfully 
targeted by both gRNAs with NHEJ. 
 
Following transfection of the gRNAs and Cas9 plasmids, clones were picked and screened for 
the absence of G4C2 repeats by repeat-primed PCR. One corrected clone was expanded for 
each of the three patient-derived lines available. The correction process is described in a 
manuscript by Dr B. T. Selvaraj (in review). The correction of the TARDBPG298S was also 
achieved using a CRISPR-Cas9 system but is more complex featuring homology-directed 
repair. This process is described in detail in Chapter 5 in which a strategy to correct the 
TARDBPM337V mutation is presented. The pairing of mutant and gene corrected lines is shown 
in Table 4. 
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G298S-1 G298S-Δ1, G298S-Δ2 
G298S-2 Not corrected 
M337V Not corrected 
Table 4: Table showing disease lines paired with their gene corrected controls. Both G298S-
1 and G298S-2 were derived from the same patient. G298S-1 has two gene corrected controls: 
G298S-Δ1 (biallelic correction) and G298S-Δ2 (monoallelic correction). 
 
Generation of spinal motor neurons from iPSCs 
 
Spinal motor neurons (sMNs) were generated from iPSCs using a previously published 
protocol (Maury et al. 2014). This work used a combinatorial approach to identify chemicals, 
doses and temporal factors capable of increasing the speed and efficiency of sMN conversions. 
Generation of sMNs from human iPSCs is shown in Figure 3. In brief, following neural 
induction with dual-SMAD inhibition by SB431542 (20μM) and LDN193189 (0.1μM), and 
potentiation with the Wnt-agonist CHIR99021 (3µM), rostrocaudal patterning is achieved 
with smoothened agonist (SAG) (500nM) and retinoic acid (RA) (1µM), respectively. DAPT 
(10µM) is then added to the sMN progenitors which markedly improves the efficiency of post-
mitotic sMN generation in a mechanism that involves inhibition of Notch signalling which 
plays a role in maintaining pluripotency (Ben-Shushan et al. 2015). 
  
Emily Rhodes Lowry modified the Maury protocol and this modified version is used by the 
Chandran lab. Rock inhibitor (10μM) has been added to the initial feed to improve iPSC 
survival following accutase dissociation. 1μM of RA was used throughout the conversion 
protocol varying from the Lowry protocol in which during the differentiation phase 100nM 
RA is used. The original analysis by Maury et al. showed no statistical difference between 
these doses however there is a trend towards an increased proportion of OLIG2 positive cells 
with the higher dose. 
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Figure 3: Diagram showing sMN generation. Abbreviations: FGF2 – fibroblast growth factor 
2; RI – Rock inhibitor; SAG – smoothened agonist; RA – retinoic acid, BDNF – brain-derived 
neurotrophic factor; DAPT – N-[N-(3,5-Diflurophenacetyl-L-alanyl)]-(S)-phenylglycine t-
butyl ester and GDNF – glial-derived neurotrophic factor. A scale bar is shown in at the 
bottom right.  
 
 
At day 16, neurospheres were dissociated and plated down into a monolayer of neurons. 
Motor neurons were maintained in motor neuron feeding media (MN-FM) for three weeks at 
which point experiments were performed. The three-week timepoint was chosen for because 




Cells were washed once with phosphate buffered saline (PBS) and fixed in 4% 
paraformaldehyde (PFA) for 20 minutes. 3% Goat serum in 0.2% Triton-X100 PBS was used 
for blocking and membrane permeabilisation. For ICC involving ChAT, the only antibody not 
raised in goat, 3% donkey serum was used instead for blocking. Primary antibodies were 
applied in 0.2% Triton-X100 PBS solution with 3% goat serum and cells were incubated at 
room temperature for 2 hours. Primary antibodies were removed and cells washed 3 times 
with PBS before secondary antibodies were added in PBS for 1 hour. Cells were then incubated 
with 4’,6-diamidino-2-phenylindole (DAPI) (1:10,000) for 5 minutes for nuclear staining. Cells 
were washed again with PBS 3 times before imaging. Concentrations used for each primary 
antibody are detailed with the relevant antibody in Table 2. Secondary antibodies were used 
at 1:1000. Cells were mounted on glass slides with FluroSave™ reagent. 
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Gene Ontology Analysis 
 
Enrichment analysis was performed on RNA sequencing (RNAseq) data using the PANTHER 
Classification System (Mi et al. 2013).  
 
First strand cDNA synthesis  
 
Three RNAseq hits involved in protein homeostasis were selected for validation with qPCR – 
HSP90B1, HSPB8 and XPO1. cDNA was synthesised using the RevertAid RT Reverse 
Transcription Kit from the same RNA samples used to generate the RNAseq data. RNA 
concentration was determined by spectrophotometry (NanoDrop1000) with a TE buffer blank. 
The manufacturer’s protocol for first strand cDNA synthesis was followed. Following 
addition of 250ng of template RNA to the random hexamers (300ng),  samples were vortexed 
and incubated at 65°C for 5 minutes before the synthesis reaction was performed with 1X 
Buffer and 1µL of Revert Aid reverse transcriptase. No template control (NTC) and no RT 
(NRT) control were performed for one sample per reaction. PCR parameters were as follows: 




Two sets of intron-spanning primers were designed for each of three target genes (HSP90B1, 
HSPB8, XPO1) using SnapGene and Primer3 softwareA. Primer annealing temperatures were 
optimised with gradient qPCR with the DyNAmo kit. The reaction mix was prepared as 
specified by the manufacturer with 1μL of 1:10 diluted control cDNA loaded per sample for 
optimisation reactions. For each pair of primers, the optimum annealing temperature and 
number of melt curve products were assessed by gradient qPCR. One primer from each pair 
was selected for efficiency analysis using a standard curve (Table 5). Three independent 
experiments were performed on the five lines each with three technical replicates, an NRT 
control and an NTC. HSP90B1 was run at 58°C with a β-actin housekeeper. HSPB8 and XPO1 
were run with a GAPDH housekeeper at 64°CB. Housekeeper primers are detailed in Table 6. 
Outliers among the technical replicates were defined as results lying out with the 95% 
confidence interval (CI). These were excluded from further analysis (25 of 313 values) and the 
mean Ct value was used to calculate expression fold change in each experiment using the 
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ΔΔCt method (Livak and Schmittgen 2001). Ct values were normalised to Con 2 and the 
relevant housekeeper (β-actin for HSP90B1, GAPDH for others). Con 2 data was not used in 
statistical analysis as by definition there was no variance between experimental replicates. The 
Kruskal-Wallis test was performed using ΔΔCt values with Dunn’s multiple comparisons 
correction in cases where the null hypothesis was refuted. Pairwise testing was not performed 





HSPB8 FW: AAGCCAGAGGAGTTGATGGT 
RV: AGGAAGCTGGATTTTCTTTGTGA 
XPO1 FW: AGCAATGCATGAAGAGGACG 
RV: CTTTGCCTCTTTTCTGTTCACA 
Table 5: Sequences of experimental group primers for RNAseq validation by qPCR. 
 
Gene Sequence 
Β-Actin FW: GTTACAGGAAGTCCCTTGCCATCC 
RV: CACCTCCCCTGTGTGGACTTGGG 
GAPDH FW: GAGTCCACTGGCGTCTTCAC 
RV: ATGACGAACATGGGGGCAT 




RNA was extracted with the RNeasy Mini Kit following the manufacturer’s protocol with no 
modifications. RNA was stored at -80°C. 
 
X-box Binding Protein 1 Splicing Polymerase Chain Reaction Assay 
 
Three-week-old sMN cultures were treated with tunicamycin 5μg/mL in normal MN-FM 
media or a DMSO by volume (0.1%) controlC. RNA was extracted 24 hours after treatment 
and quantified by spectrophotometry (NanoDrop1000). cDNA was synthesised as described 
in Quantitative PCR with 100-250ng of total RNA per reaction depending on the RNA yield. 
To amplify both the full length and spliced ATF6 transcripts, previously published primers 
were used (see Table 7) (Samali et al. 2010). 
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Primer Sequence 
XBP1 Forward TTACGAGAGAAAACTCATGGCC 
XBP1 Reverse GGGTCCAAGTTGTCCAGAATGC 
Table 7: XBP1 primer set used by Samali et al. 
 
30μL PCR reactions with 4 units Q5® High-Fidelity DNA Polymerase, x1 Q5® High-Fidelity 
2x Master Mix, dNTPs (200nM) nuclease-free water and 5μL cDNA. 5μL PCR product mixed 
with Gel Orange and run on 1% agarose gel (1g agarose in 100mL TAE buffer with 5μL Gel 
Red) with 50bp and 100bp reference ladders for 1 hour at 100V. 
 
Protein Extraction and Quantification 
 
Soluble and insoluble protein fractions were obtained following lysis with 
radioimmunoprecipitation assay (RIPA) buffer. RIPA buffer was prepared fresh with 50mM 
Tris-HCl (pH 7.4), 150mM NaCl, 1% Triton-X100, 0.5% sodium deoxycholate, 0.1% SDS, 2mM 
EDTA, 1x protease inhibitor and 1x phosphatase inhibitor in water. Following cell lysis, 
samples were centrifuged at 13,000rcf for 30 minutes at 4°C. The supernatant was collected as 
the soluble fraction.  200μL of PBS was added to the pellet followed by centrifugation again at 
13,000rcf for 10 minutes at 4°C. The PBS wash was removed and 75μL of urea buffer (Table 8) 
was added and the sample incubated on ice for 10 minutes before sonication on ice for 5 
seconds. Samples were centrifuged a final time at 13,000rcf for 30 minutes at 4°C and the 
supernatant was taken as the insoluble fraction. Proteins were stored at -20°C short term and 
-80°C long term. 
 




Trizma® Base 30mM 
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Protein concentration was estimated using a bicinchoninic acid (BCA) assay carried out as 
described by the manufacturer with the following alterations. A 1mL reaction mix of Reagents 
A and B was used (instead of 2mL) and correspondingly 50μL of protein added (instead of 
100μL). Absorbance at 562nm was determined using an Eppendorf BioPhotometer with a 
RIPA blank. A standard curve was produced using the ‘Test Tube’ protocol. Three technical 
replicates were performed and the mean calculated. Mean absorbance was plotted against the 
concentration Figure 4. 
 
 
Figure 4: BCA standard curve produced using the Test Tube protocol. Each point represents 
the mean of three technical replicates. A linear model with intercept = 0 was fitted of the form 
y=0.0016x (R2=0.9979). 
 
Protein concentrations were subsequently determined as: 
 





𝑚 is the gradient of the standard curve, 𝐴 is the absorbance and 𝐷𝐹 is the dilution factor of 
























BCA Assay Standard Curve
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Western Blots 
 
Following determination of protein concentration by BCA, Laemmli buffer (X5) (Table 9) was 
added to 10 – 30μg protein samples with volumes equalised with RIPA bufferD.  
 
Substance Quantity 
1M pH 6.8 3.5mL 
Glycerol (100%) 5mL 
SDS 1g 
1% Bromophenol blue 0.125mL 
β-ME 1mL 
H2O 0.875mL 
Table 9: Laemmli buffer (X5) composition. 
 
Samples and protein ladders were loaded into 4 – 20% polyacrylamide gels and run at 150V 
until the bromophenol blue running front had reached the bottom of the gel. Protein was then 
transferred to a methanol-activated PVDF membrane (Immobilon®-P, Merck, IPVH00010) and 
transferred using a MiniGel Tank (Life Technologies) at 20V for 1.5 hours. Following transfer, 
membranes were blocked for 1 hour with 5% milk in TBS-T. Primary antibodies against targets 
ATF6 (1:1000), PERK (1:1,000), calnexin (1:10,000) or GAPDH (1:10,000) were added in 5% 
milk in TSB-T and left overnight at 4°C.  Following three TBS-T washes HRP-conjugated 
secondary antibodies were added in 5% milk in TBS-T for 1 hour. Three more TBS-T washes 
were performed before membranes were exposed to detection Amersham ECL detection 
solutions for 5 minutes. Amersham ECL Prime was used for highly expressed proteins while 
Select was used for less abundant proteins. Membranes were exposed on radiographic film 
(Amersham hyperfilm MP, GE, 28906842). Band intensity was quantified by densitometry 
(Image J, Gel Analysis Plugin). 
 
For Western blots using samples from the insoluble protein fraction, BCA could not be 
performed accurately because of the composition of the urea buffer. In these cases, equal 
volumes of protein were subject to electrophoresis followed by Coomassie staining and 
densitometric band analysis to determine ratios that would allow equal loading of samples. 
Following Western blotting, the membrane was again stained with Coomassie to confirm 
equivalent loading.  
44 | P a g e  
 
MScR The University of Edinburgh 2017 
 
Tunicamycin Survival Analysis 
 
Survival assays determining the effect of tunicamycin on neurons derived from 8 iPSC lines 
(Con 1, Con 2, C9-1, C9-Δ1, C9-2, C9-Δ2, C9-3, C9-Δ3) were performed at three weeks post 
platedown. Calcein AM was used as a fluorescent reporter of cell viability.  Esterases produce 
an acetoxymethyl (AM) derivative of calcein (calcein AM), which is trapped in cells with intact 
membranes hence the intensity of calcein AM is a measure of membrane integrityE. Three half 
media changes were used to dilute existing MN-FM media with a basal media (neurobasal 
(X1), B27 (X50), PSF (X100) and GlutaMax(X100)) to exacerbate any phenotype. Calcein was 
added at 4µM and 0h imaging performed at 488nm at x10 magnification with a Zeiss 
microscope with incubation at 37°C. Image parameters were kept constant over each 48h 
experiment but varied between replicates. Following imaging, cells were subjected to 
tunicamycin at 1μg/mL, 3μg/mL, 5μg/mL, 10μg/mL or a DMSO (matched by volume) control 
in basal media. Repeat imaging was undertaken at 24h and 48h. Prior to each subsequent 
imaging period was a half media change with basal media supplemented with calcein AM. 
Note that drugs were not re-added during these media changes thus the concentration of drug 
in the media reduced by approximately 50% every 24 hours in addition to the decay resulting 
from the half-life of the drug. There was insufficient literature to establish this in this culture 
system. 
 
Stacks were prepared for each well imaged containing the baseline, 24h and 48h images. The 
resulting images were to be analysed by manual cell tracking through stacks. Concerns 
regarding the precision of these measurements lead to attempts to develop alternative 
analysis protocols one of which is described and is based on the determination of cellular 
mean integrated density. 
 
Manual Cell Tracking 
 
If cells could be accurately and precisely classified as alive or dead cell tracking would prove 
an excellent way to analyse survival. Biological systems are rarely so simple though and 
different markers of life and death have their advantages and disadvantages. Calcein was 
used because of prior experience in the lab of this technique. As with many other survival 
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techniques, the intensity of calcein AM fluorescence is a function of membrane integrity. 
Compromise of cell membranes, as occurs during cell death, results in leakage of the dye into 
the extracellular space reducing the intensity of the cell. The following observations have been 
made in sMN cultures treated sequentially with calcein AM over 48 hours as described above: 
 There is a marked increase in the background intensity. Background fluorescence is 
present at very low levels initially and this is said to result from the activity of a low 
level of extracellular esterases, it is hypothesised that this increase in intensity reflects 
(activated) calcein AM released from compromised cells (Figure 5). 
 
 
Figure 5: Increasing background over sequential imaging caused by leakage of calcein AM 
into the extracellular space or activation of added calcein by extracellular esterases. The 
time of imaging is shown in the top left-hand corner. Heterogeneity in fluorescence is also 
observed with a brighter signal towards the edges of the well. 
 
 A subpopulation of cells increases in intensity over the 48h window. This population 
of cells is the only one easily visualised by eye (see Figures 6 and 7).  
 The signal of a cell is rarely completely abolished. If cells do not increase in intensity 
as described above, they may remain at a stable intensity or decrease. 
 Heterogeneity in fluorescence is observed across plates with some regions of the well 
(which correspond to those in which pipette tips have been introduced) less likely to 
house brightly fluorescing cells (see Figure 5). 
 
These phenomena and others have important implications for the use of calcein in survival 
analysis. Two additional features that complicate survival analysis in our cultures are 
clustering and cell movement. The problem of clustering in MN cultures is well described and 
approaches to resolve the problem including dissociation of mature MNs remain lacking. 
0h 24h 48h 
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Advantages can be expected with the invention of new plate technologies but at present, we 
have reduced the levels of clustering with very low-density platedowns. This technique was 
developed for neurite outgrowth analysis and is suboptimal for survival analysis because 
survival in these low-density cultures does appear to be reduced. At a platedown density of 
20,000 cells per well of a 96 well plate, we observe both clusters and single cells. In the cultures, 
cells that cannot be identified as discrete units using the calcein AM signal alone are ignored 
for manual cell tracking analysis. The use of live nuclear dyes has been considered and tested, 
however, these cultures are laden with a large amount of DAPI-positive debris. These bodies 
are small, circular and extremely brightly staining. They complicate identification of cells with 
nuclear markers for which they are often positive and this, in concert with cellular clustering, 
makes identification of single cells extremely challenging. I have made attempts to remove 
this debris using DNAase and washes but have not been successful. Additionally, designing 
computational algorithms that identify cell nuclei becomes extremely difficult. In addition to 
these issues, MNs move a small degree during culture and we have observed isolated cells 
moving to join clusters with longitudinal imaging. These factors make designing algorithms 
to track cells over the 48 hours very complex so manual cell tracking was used at the expense 
of the sample size. 
 
Images were divided into forty-nine sampling regions using a seven by seven grid with a 
perimeter. The perimeter functioned to prevent inclusion of cells which might migrate beyond 
the image capture zone. One cell was sampled from each region containing cells. In the 
majority of wells, all regions contained cells and thus 49 cells were sampled per experiment. 
The number of experimental replicates completed varies among cells lines as some gene-
edited controls were developed over the course of the MSc. The sample size for each line is 
shown in Table 10. Within the sampling region, discrete neuron-like cells were selected 
(astrocytic-type cells were very rarely observed but have a distinct morphology). Cells close 
to clusters were avoided to reduce the change of them being lost to follow up. Cells that were 
thought to join a cluster were treated as dead in keeping with the intention to treat analysis 
protocol. Cells were judged alive if the level of fluorescence was maintained or increased 
relative to the previous imaging session. 
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Line Number of images Number of cells 
Con 1 17 817 
Con 2 17 833 
C9-1 17 833 
C9-Δ1 17 833 
C9-2 17 832 
C9-Δ2 15 699 
C9-3 12 588 
C9-Δ3 5 385 
Table 10: Table showing the number of images and cells for each line subject to manual 
survival analysis. 
 
Command line and ImageJ scripts were written to organise images into stacks, blind images 
by removing slice labels and applying pseudo-random titlesF and apply grids. Variable cell 
size precluded effective use of a rolling-ball background subtraction algorithm. Images in 
which there was thought to be a quality control issue were excluded before blinding was 
removed. Quality control issues were infrequent but included: 
 Exposure time too low 
 Pipette damage 
 Lifting of cells from LMF 
 
Mean Cellular Integrated Density 
 
The fluorescence of cellular units (discrete and clumped neurons) over the course of the 
experiment provides an indication as to the integrity of their membrane and thus their 
viability. The addition of calcein before each imaging cycle means that cells should be able to 
take up new calcein and convert this to calcein AM increasing, or at least maintaining their 
fluorescence. Membrane compromise would allow calcein AM to escape. For this reason, the 
intensity of a cell provides an indication of viability. To overcome the limitation of counting 
calcein AM in the extracellular space, algorithms to measure cellular units were employed. To 
ensure reproducibility and throughput the 17 auto-thresholding algorithms on ImageJ were 
trialled on a minimum of fifteen images (0h, 24h and 48h) using a custom-made macro. 
Although all auto-thresholding algorithms were applied, some are clearly inappropriate 
because of their mathematical foundations. Algorithms were assessed by judging the cellular 
masks formed (Cellular overlays in Figures 6 and 7) at 0, 24 and 48 hours (below). The best 
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performing algorithm, Moments, is shown below applied to representative images of high 
and low survival. Below each image are tables detailing the mean cellular grey value, the 
mean cellular integrated density and survival as determined by manual cell tracking. 
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Example (High Survival)  
 
Figure 6: Representative images of a well with high survival over the 48h imaging period. 
The first row shows raw images. The second row shows region of interest (ROI) masks 
generated by the Moments algorithm. The last row shows the outline of the ROIs created by 
Moments applied to the raw image and requires visualisation at high magnification. 
 
 Baseline (0h) 24h 48h 
Mean Grey Value (Cellular)  100.00% 187.64% 208.66% 
Mean Normalised Integrated Density 
(Cellular) 
100.00% 75.14% 45.83% 
Manual Cell Tracking Percentage 
Survival 
100% 71.43% 28.57% 
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Example (Low Survival) 
 
Figure 7: Representative images of a well with low survival over the 48h imaging period. 
The first row shows raw images. The second row shows region of interest (ROI) masks 
generated by the Moments algorithm. The last row shows the outline of the ROIs created by 
Moments applied to the raw image and requires visualisation at high magnification. 
 
 Baseline (0h) 24h 48h 
Mean Grey Value (Cellular)  100.00% 62.98% 81.75% 
Mean Normalised Cellular  Integrated 
Density 
100.00% 63.47% 15.07% 
Manual Cell Tracking Percentage 
Survival 
100.00% 93.88% 6.12% 
Table 12: Measures of viability over the 48h imaging period corresponding to Figure 7.  
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Integrated density is calculated by multiplying the mean grey value of a region of interest by 
its area. It can be seen from the tables above that mean grey value alone performs very poorly 
because it takes no account for the decreasing area of cells that follows death. Mean cellular 
integrated density proves a better surrogate for cellular viability. Given the subjectivity and 
variability of manual cell tracking described above it is argued that analysis by both manual 
cell tracking and mean normalised cellular integrated density (from this point on referred to 
as mnID) prove complementary. Manual cell tracking has the advantage of providing 
biologically meaningful units but suffers from subjectivity and is slow. mnID can be applied 
to a much larger sample size and takes into account the survival of clusters of neurons, not 
just individual cells. It is, however, less interpretable particularly considering it can increase 
over the course of 48h given that more calcein is added prior to each imaging session. 
Following calculation of the normalised mnID for all samples, every mask was screened. 33 
of 422 masks were excluded (6.85%) because of poor fit. 
 
Statistical Approach to Survival Data 
 
The statistical analysis of this dataset is complex. Details are provided with results, but the 
general strategy has been to produce mixed linear regression models which allow important 
factors and covariates to be explored before construction of models with and without a 
dependent variable of interest. By constructing models with and without the dependent 
variable under investigation the effect of that variable on the performance of the model can 
be assessed. The best method of comparison is debated among statisticians – here the 
likelihood ratios test has been applied. It is acknowledged that the use of mixed linear 
regression models does not take into account the right censoring of this dataset. It does, 
however, allow multiple variables to be incorporated including random effects which is 
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TARDBP Genotype Validation PCR 
 
DNA was extracted using the Wizard® SV Genomic DNA Purification System using 
centrifugation. Primers generating a 452bp amplicon within exon 6 spanning the mutation site 
were used (Table 13). 
 
Primer Sequence 
TARDBP Forward TTGCGCAGTCTCTTTGTGGA 
TARDBP Reverse GGATGCTGATCCCCAACCAA 
Table 13: Primers used for the amplification of a 452bp region of TARDBP exon 6. 
 
The PCR reaction mix consisted of 0.5U Q5® High-Fidelity DNA Polymerase, Q5® Reaction 
Buffer, 0.2mM dNTP, 1.25μL 10μM TARDBP Forward Primer, 1.25μL 10μM TARDBP Reverse 
Primer and 100ng cDNA made to 25μL with nuclease-free water. 
 
Successful amplification was determined by gel electrophoresis (1% agarose in TAE Buffer) to 
identify the 452bp amplicon. Samples with successful amplification were sent for Sanger 
Sequencing (Source Biosciences). 
 
 
Chapter 2: Materials and Methods Notes 
 
A – Intron-spanning primers were used to reduce the chance of contamination through 
genomic DNA amplification. 
B – The choice of the housekeeper was determined by the annealing temperature of the primer 
allowing target and housekeeping genes to be run on the same plate. These primers have 
previously been optimised by the Chandran lab.  
C – Tunicamycin is constituted in DMSO. 
D – The exact mass of protein used was equal to the minimum yield or 30μg (whichever was 
lower).  
E – The expression pattern of calcein AM in neurons has been reported previously with 
relatively high emission from the soma than processes (Hancock et al. 2015).  
F – The ImageJ macro used for obfuscation was written by Tiago Ferreira.  
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When originally characterised the Maury sMN differentiation protocol produced 
approximately 70% HB9+/ISLET1+ cells. In our hands over 95% of cells are MAP2+ and less 
than 5% of cells stain positive for the astrocyte marker GFAP at three weeks. At the three-
week timepoint, ChAT expression is developing and becomes more abundant with time in 
culture (Figure 8).   
 
Figure 8: Representative images of cells positive for the pan-neuronal marker MAP2 and 
sMN markers ISLET1/2 and ChAT. Three-week-old sMN cultures were stained for the pan-
neuronal marker MAP2 and sMN markers ISLET1/2 and ChAT along with the astrocyte 
marker GFAP. Left: > 95% of nucleic identified by DAPI (blue) colocalise with MAP2 (red), 
X10 magnification. Right: Positive staining for sMN markers ISLET1/2 (green) in all cells and 
ChAT (white arrow). 
 
GO Analysis of RNAseq data 
 
Lists of differentially expressed genes established by RNA sequencing (RNAseq) of three-
week control, C9ORF72 mutant and gene corrected sMN cultures were provided by Professor 
Hardingham. Gene ontology (GO) analysis was performed and of the 85 upregulated genes, 
four IDs were unmapped and correspond to non-protein coding genes (Supplemental Table 
1). Of the 80 downregulated genes, 14 were non-protein coding (Supplemental Table 1). A 
complete list of RNAseq hits is provided by Dr B. T.  Selvaraj et al., (in review). 
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Data from PANTHER protein class GO analysis is shown below in Figure 9. 
 
 
Figure 9: The fold enrichment of PANTHER protein class terms in C9ORF72 mutant lines 
following GO analysis of RNAseq data. Note that data on up- and downregulated 
transcripts are presented together. 
 
Transcripts coding for a wide range of protein classes were identified as being significantly 
dysregulated in C9ORF72 mutant lines. As TDP-43 pathology is a common feature in most 
forms of MND and chaperone proteins were identified following GO analysis we decided to 
validate several candidate proteins involved in the unfolded protein response (UPR) by qPCR.  
 
Validation of RNAseq Hits 
 
Three transcripts were selected for validation based on the GO results – HSP90B1, HSPB8 and 
XPO1. RNA samples from three-week-old sMN cultures were subject to qPCR with 
appropriate housekeepers (see Methods). 
 
Of the 313 Ct values obtained 25 outliers were removed (7.99%) as described in Methods. The 
expression fold changes for each investigated transcript are shown below (Figures 10, 11 and 
12) and ΔΔCt values can be found in Supplemental Table 2.  RNAseq hits were considered 
validated if the ΔΔCt varied significantly from the control (α = 0.05) in C9ORF72 mutant lines 
but not in gene-corrected control. Analysis has been undertaken on data both with and 
without outlier exclusion. Analysis of data without outlier exclusion is provided in 
Supplemental Figures 1, 2 and 3 and Supplemental Table 3. 
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HSP90B1 
 
HSP90B1, a chaperone involved in ER-associated degradation (ERAD) (Di et al. 2016), was 
upregulated on RNAseq. The RNAseq data was not validated by the qPCR (Figure 10) but 




Figure 10: C9ORF72 mutants show heterogeneity in HSP90B1 transcript expression. 
Expression fold change of HSP90B1 transcript in control (green), C9ORF72 mutant (red) and 
gene corrected (blue). Outliers have been removed. Each point represents data from an RNA 
sample from an independent sMN conversion. Black bars mark the mean. Error bars show the 
95% CI. Kruskal-Wallis refuted the null hypothesis with (p = 0.0406). Dunn’s multiple 
comparisons test was performed and results are shown in Table 14. A significant increase in 
HSP90B1 expression was observed in C9-3 but not C9-1. 
 
Comparison P value 
Con1 vs. C9-1 > 0.9999 
Con1 vs. C9-3 0.0369 
Con1 vs. C9-Δ1 > 0.9999 
Table 14: Results of Dunn’s multiple comparisons test for HSP90B1. 
  
* 
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HSPB8 
 
HSPB8, a chaperone implicated in the clearance of TDP-43 aggregations (Crippa et al. 2016), 
was also identified as upregulated on RNAseq. This result was confirmed by qPCR (Figure 
11, Table 15). In addition to significant upregulation in C9-1 and C9-3, there was also rescue 
in the gene-corrected line C9-Δ1. 
 
 
Figure 11: HSPB8 is expressed at significantly higher levels in C9ORF72 mutant lines but 
at lower levels in gene-corrected lines. Plots showing expression fold change of HSPB8 
transcript in control (green), C9ORF72 mutant (red) and gene corrected (blue) sMN RNA. 
Each point represents the mean of three technical replicates from RNA samples from 
independent sMN conversions. Black bars mark the mean. Error bars show the 95% CI. 
Kruskal-Wallis refuted the null hypothesis with p = 0.0072. Dunn’s multiple comparisons test 
was performed and results are shown in Table 15.   
Comparison P value 
Con1 vs. C9-1 0.0216 
Con1 vs. C9-3 0.0273 
Con1 vs. C9-Δ1 0.3911 
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XPO1 
 
XPO1 functions in nucleocytoplasmic shuttling (Fornerod et al. 1997). Although XPO1 
narrowly failed adjustment for multiple comparisons in the RNAseq analysis it was 
investigated because of recent evidence in support of nucleocytoplasmic transport deficits in 
iPSC and post-mortem brain tissue from individuals with C9-MND (Zhang et al. 2015). No 
significant variation in XPO1 transcript expression was observed between control, C9ORF72 
mutant and gene corrected lines (p = 0.3340) (Figure 12). 
 
 
Figure 12: XPO1 is not differentially expressed in three-week sMN cultures with the 
C9ORF72 HRE. Expression fold change of XPO1 transcript in control (green), C9ORF72 
mutant (red) and gene corrected (blue) sMN RNA. Each point represents the mean of three 
technical replicates from RNA samples from independent sMN conversions. Black bars mark 
the mean. Error bars show the 95% CI. Kruskal-Wallis failed to refute the null hypothesis with 
p = 0.3340.  
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Endoplasmic Reticulum Stress Sensors 
 
Following validation of HSPB8 upregulation and heterogeneity among C9ORF72 mutant lines 
in HSP90B1 expression further investigation into the possibility of ER stress in C9ORF72 
mutants was undertaken. The activation of three UPR stress sensors (IRE1, PERK and ATF6) 




A 26 base pair long nucleotide sequence of the XBP1 transcript is removed by unconventional 
splicing by activated IRE1 (Yoshida et al. 2001). The spliced XBP1 transcript codes for a stable 
transcription factor which can bind to ER stress response elements (ERSE) with potentially 
pro-survival or apoptotic consequences. Inability to mount an XBP1 response appears to be 
neuroprotective in cellular and rodent models of MND (Hetz et al. 2009). 
 
The ability to detect XBP1 splicing via the PCR technique described was assessed on two lines: 
HB9-GFP and G298S (Figure 13). 
 
 
Figure 13: XBP1 splicing can be detected in sMN cultures treated with 5μg/mL or 10μg/mL 
tunicamycin for 24h. Data from two cell lines are shown: HB9-GFP (left) and G298S (right). U 
= untreated cells (full media change only), T5 = tunicamycin at 5μg/mL for 24 hours prior to 
RNA extraction, T10 = tunicamycin at 10μg/mL for 24 hours prior to RNA extraction. The 
upper band is at 283bp. The spliced 257bp product is observed below in cells treated with 
tunicamycin. In G298S there is no evidence of spliced XBP1 at rest which is interesting 
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Following confirmation spliced XBP1 transcript could be detected, C9ORF72 mutant and 
control sMN cultures under normal conditions (no treatment) were assessed for XBP1 
splicing which would indicate ER stress (Figure 14). 
 
 
Figure 14: Unspliced XBP1 transcript is observed in control, C9ORF72 mutant and gene-
corrected controls but the active spliced fraction is not. Following the 100bp ladder cDNA 
samples from one control line and three C9ORF72 mutants with gene-corrected controls have 
been subject to XBP1 PCR and run on a 2.5% agarose gel.  
 
Figure 14 shows that in normal culture conditions C9ORF72 mutant sMNs do not show 
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The response of C9ORF72 mutant sMNs to proteostatic insult via tunicamycin administration 




Figure 15: XBP1 splicing occurs in control, C9ORF72 mutant and gene corrected sMN 
cultures at three weeks treated with 5μg/mL tunicamycin but not a DMSO by volume 
control. Left: Gel electrophoresis showing unspliced XBP1 transcript following DMSO 
treatment and both unspliced and spliced XBP1 transcript following treatment with 
tunicamycin in all lines. The far left lane houses a 100bp ladder. Right: Plot showing the ratio 
of spliced to unspliced XBP was established by densitometry and the ratio of the spliced band 
to the unspliced band calculated. This ratio allows normalisation for random variability in 
PCR product loading. Data from one control line, three C9ORF72 mutants and their gene-
corrected partners are shown. Each data point represents an independent sMN conversion. 
Error bars show the 95% CI. Further replication is required. Statistical analysis with such low 
n values would be inappropriate at this point, however, this data when expanded upon would 
likely be suitable for ANOVA or Kruskal-Wallis depending on whether or not data is normally 
distributed. 
 
This data suggests that the XBP1 splicing response of C9ORF72 mutant sMNs does not vary 
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PERK 
 
Under conditions of ER stress, GRP78 dissociates from PERK leading to its oligomerization 
and autophosphorylation. Levels of total PERK have been demonstrated to be upregulated in 
the spinal cords of patients with MND at post-mortem (Atkin et al. 2008). Under basal 
conditions, PERK expression did not differ between control, C9ORF72 mutant, TARDBPG298S 




Figure 16: Total PERK levels do not vary between control, C9ORF72 mutant and 
TARDBPG298S mutant cell lines under normal conditions. A) Representative Western blot 
showing equal levels of total PERK (~140kDa) across control, C9ORF72 and TARDBPG298S 
lines. A GAPDH housekeeper is shown below. B) Plot showing band intensity from Western 
blotting determined by densitometry. Total PERK level was normalised to housekeepers and 
this ratio was then normalised to a single line (C9-1) and expressed as a fold change. Each data 
point represents an independent sMN conversion and subsequent independent experiments. 
N equals 1 for all lines except: Con 1 = 2, C9-1 = 3, C9-Δ1 = 3, C9-2 = 3 and C9-Δ3 = 3. Error bars 
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To confirm PERK upregulation upon ER stress could be detected, cells were treated with 
tunicamycin (5μg/mL) for 24h. Figure 17 demonstrates a representative blot of PERK 




Figure 17: Upregulation of PERK on treatment with tunicamycin. A) Western blot showing 
upregulation of PERK with tunicamycin treatment. PERK is visible at ~ 140kDa. Calnexin was 
used as a loading control. B) Band intensity from Western blotting on samples treated with 
5μg/mL tunicamycin or a DMSO control has been determined by densitometry. Total PERK 
level was normalised to housekeepers for both tunicamycin and DMSO cells. A ratio of 
normalised PERK levels in tunicamycin to DMSO treated groups was calculated – termed the 
Total PERK expression fold change upon tunicamycin treatment (y-axis).  Each data point 
represents an independent sMN conversion with subsequent independent experiments. N 
equals 1 for all lines except: C9-1 = 2 and C9-Δ1 = 2. Error bars show the 95% CI.  
 
Quantitative analysis of band intensity was carried out to determine the response of different 
cell lines to tunicamycin treatment. The interpretation of these results is limited due to the low 
sample size examined so far, however, there is some evidence of a differential PERK response 
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ATF6 
 
Cleaved fractions of ATF6 in ER stress translocate to the nucleus where they bind to ER stress 
response elements (ERSEs) in gene promoters which are capable of inducing both pro-survival 
and pro-apoptotic changes (Yoshida et al. 1998). 
 
Protein samples from three-week-old sMNs cultured in normal conditions were probed for 
ATF6 on Western blotting. Multiple positive bands were observed (Figure 18). The ~100kDa 
band corresponds to full-length ATF6. Spliced products are observed at ~80kDa, ~67kDa, 
~57kDa, ~37kDa, ~30kDa, ~27kDa and ~15kDa. The intensity of these bands varied between 
samples. The analysis focused on the ratio of full-length ATF6 to the 37kDa cleaved fragment. 
The 37kDa band has been previously associated with cell stress using a different anti-ATF6 
antibody (Mao et al. 2007). 
  
64 | P a g e  
 






Figure 18: The 37kDa cleaved ATF6 fragment is present at higher levels in TARDBPG298S 
mutants with heterogeneous ATF6 cleavage among C9ORF72 mutants. A) Western blot for 
ATF6. Full-length ATF6 runs at approximately 100kDa. 60kDa, 50kDa and 37kDa cleaved 
fractions have also been reported. Additional fragments were observed around 80kDa, 67kDa, 
two further fractions at approximately 30kDa and a 15kDa fraction. Anti-ATF6 antibody was 
applied and the membrane probed prior to treatment anti-GAPDH and sodium azide 
excluding the possibility that the 36kDa fragment observed in the Anti-ATF6 Western blot is 
a GAPDH signal. B) Plot showing the densitometric ratio of 37kDa cleaved/full-length ATF6 
in all lines. Controls are in green, C9ORF72 mutants in red, C9ORF72 gene corrections in blue 
and the TARDBP mutant and gene corrections in black. Levels of the spliced product are seen 
to be considerably higher in TARDBPG298S mutants and also in their gene corrected partners 
suggesting the effect may be independent of the mutation – replication is required. C) A repeat 
of plot B with the TARDBP mutant and gene corrected lines removed to allow visualisation 
of this parameter in control and C9ORF72 lines. While the ratio of ATF6 products is very 
similar in C9-1 it is interesting that C9-2 displays greater levels of the spliced product that its 
gene edited partner. The C9-2 levels are roughly comparable to that of Con 1. 
 
Although the small sample size prohibits statistical analysis, there is a clear trend to an 
increased abundance of the 37kDa cleaved ATF6 protein in TARDBPG298S mutants and gene 
corrected partners suggesting constitutive activation of this UPR stress sensor independent of 
the G298S mutation. In C9ORF72 mutants heterogeneity is again observed with little AFT6 
cleavage in C9-1 but greater quantities in C9-2, some of which appears to be dependent on the 
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Following examination of the constitutive state of ATF6 cleavage, this pathway was 




Figure 19: Heterogeneous ATF6 cleavage among C9ORF72 mutant lines in response to 
tunicamycin may provide evidence for HRE toxicity modifiers. A) Western blot for ATF6 
showing upregulation of full-length ATF6 on treatment with tunicamycin which appears to 
be more prominent in C9ORF72 and TARDBPG298S mutants. The first five samples are 
untreated. The next five samples were treated with 5μg/mL tunicamycin for 24 hours prior to 
protein extraction. G298S-Δ2 was included as a positive control. B) Graph showing the 
expression fold change in the ratio of the density of the 110kDa ATF6 product to that of the 
37kDa product. The y-value is calculated in two steps. First, the ratio of full-length ATF6 to 
that of the 37kDa cleaved product is established in cells treated for 24 hours with 5μg/μL (5μL) 
tunicamycin (T) or a 5μL DMSO (D) control at three weeks of age. Each line was thus 
described with two values – indicating the abundance of the 37kDa spliced product relative 
to the full-length protein after DMSO or tunicamycin treatment. The tunicamycin treatment 
value was then divided by that of the DMSO value to determine the expression fold change 
of ATF6 cleavage following tunicamycin treatment. Only one experiment has been performed 
so variance cannot be assessed. Controls are in green, C9ORF72 mutant lines in red and gene 
corrected partners in blue. Mirroring the results obtained on examination of constitutive ATF6 
cleavage it can be seen that in C9-2 the C9ORF72 HRE seems to confer an exaggerated response 
to tunicamycin which is significantly greater this time than that of the control line. This may 
suggest the presence of an HRE toxicity modifier active within C9-2. 
 
On examination of Figure 19, upregulation of full-length ATF6 was apparent in tunicamycin-
treated lines and in G298S-Δ2 that was used as a positive control. To allow comparison of 
samples from independent conversions, samples were first normalised to a housekeeper and 
then normalised to C9-Δ1A. C9-Δ1 was chosen as it was present in all experiments. 
 
The ATF6 cleavage response of the C9ORF72 lines to tunicamycin to some extent mirrors their 
basal ATF6 cleavage status. It can be seen that once again C9-1 and C9-2 respond differently. 
A B 
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Cleaved ATF6 in C9-1 is comparable to that of the control line and appears independent of 
C9ORF72 repeat expansion mutation. In C9-2, the HRE appears to confer upon sMN cultures 
an increased response to tunicamycin in the form of greater production of the ATF6 37kDa 
cleaved fragment. This provides some evidence again for heterogeneity of C9ORF72 
pathophysiological processes though replication is required. 
 
sMN culture survival analysis following tunicamycin-induced ER stress 
 
With validation of HSPB8 upregulation in C9ORF72 mutants and evidence that sMNs from 
patients carrying the C9ORF72 HRE might respond differently to ER stress induced by 
tunicamycin, the effect of tunicamycin on the survival of these cultures was investigated. 
Evidence of ER stress in C9-MND iPSC-derived MNs is already reported in the literature 
(Haeusler et al. 2014) and we sought to replicate these findings. Tunicamycin at doses ranging 
from 1μg/mL to 10μg/mL was administered to three-week sMN cultures with viability 
assessed at 24 and 48 hours. Viability was assessed by two methods, which are presented as 
complementary – manual tracking of a sample population of cells and analysis of the mean 
normalised integrated density of wells (see Methods). 
 
The primary goal of the analysis was to test the hypothesis that the C9ORF72 mutation 
resulted in a progressive decrease in sMN viability after induction of ER stress.  The data were 
analysed using mixed linear models. Construction of these models is iterative so before the 
hypothesis was tested, data on platedown variability and the relationship between 
tunicamycin dose and viability were first analysed to allow construction of an appropriate 
model. The covariates/factors considered in the analysis are detailed in Table 16. Independent 
variables are detailed in Table 17. 
Covariates/Factor Name Description 
Genotype Control, C9ORF72 mutant or gene-corrected 
Line Cell line used: Con 1, Con 2, C9-1, C9-Δ1, C9-2, C9-Δ2, C9-3 or 
C9-Δ3 
Dose Tunicamycin dose in μg/mL: 0, 1, 3, 5 or 10 
Place down A letter assigned to each different sMN conversion and 
subsequent independent experiments: A – H 
Table 16: Table showing covariate and factor names used in the tunicamycin survival 
analysis. 
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Independent Variable Description 
24h survival The percentage survival at 24h as determined by manual cell 
tracking 
48h survival The percentage survival at 48h as determined by manual cell 
tracking 
24h mean normalised 
integrated density(mnID) 
The mnID at 24h determined using the Moments algorithm. A 
surrogate marker for survival. 
48h mean normalised 
integrated density(mnID) 
The mnID at 48h determined using the Moments algorithm. A 
surrogate marker for survival. 
Table 17:  Table showing the independent variables measured in the tunicamycin analysis.  
In brief, normalised integrated density (nID) is equivalent to the total quantity of activated 
calcein (calcein AM) within a cell and is calculated by multiplying the intensity of calcein AM 
fluorescence by the cell area and normalising this result to that of the baseline 0h image. The 
nID is reported calculated for each individual cell or cluster of cells. To avoid 





The first factor considered was variability in platedown. It was hypothesised that data would 
be clustered by platedown which could have important implications for subsequent statistical 
analysis. The relationship between platedown and viability at 48h is displayed graphically 
below (Figure 20).  
 
Figure 20: There is considerable variability in the mean normalised integrated density 
(mnID) between platedowns at 48h. Points show the mean of the mean normalised integrated 
density. Error bars show the 95% CI. The number of wells from which mean normalised 
integrated density for each platedown was calculated is: A = 61; B = 53, C = 60, D = 54, E = 21, 
F = 18.  
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Such variance between platedowns is unsurprising. Some of this variance likely results from 
other measured factors including variability between cell lines and tunicamycin doses used 
across experiments. Other confounding variables will include factors such as variance in the 
sMN differentiation protocol, calcein AM batch, plate batch, optical parameters and exact 
imaging time.  
To investigate whether controlling for cell line, sMN age and dose could account for this 
variance a subset of data was sampled. With the above factors matched there was still a large 
amount of variability in mnID at 48h (data not shownB). It is therefore concluded that 
platedown should be treated as a random effect with respect to the statistical analysis of this 
dataset. 
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Tunicamycin dose 
 
Having established the importance of the effect of platedown in explaining variability 
between experiments, the relationship between genotype, dose and the two measures of 
viability (manually determined survival and mnID) was investigated (Figure 21). 
Figure 21: Plots showing two different assessments of the viability of three-week-old sMN 
cultures in response to a range of tunicamycin doses. Controls are shown in green, C9ORF72 
mutants in red and gene corrected controls in blue. A key at the top right allows assessment 
of the response of individual cell lines denoted by signals. Points denote the mean and error 
bars the SEM. The top row of plots shows the percentage of neurons that survived to 24 (A) 
and 48 (B) hours as determined by manual cell tracking. Survival in all lines at 24 hours is 
above 50% dropping to below 50% for most lines at 48 hours.  A) At 24 hours there does not 
appear to be a consistent deficit in survival following administration of increasing doses of 
tunicamycin. B) By 48 hours, a trend towards decreased percentage survival with increasing 
doses of tunicamycin is observed. The bottom row of plots shows the relationship mean 
normalised integrated density (mnID), a survival proxy, and tunicamycin dose. In contrast to 
percentage survival, the mnID does not decrease significantly between 24 (C) and 48 hours 
(D). The addition of calcein AM prior to imaging means the mnID of viable cells will remain 
constant or increase. C) Again, no clear relationship between mnID and increasing 
tunicamycin dose is evident at 24 hours. Note that SEM error bars in two cases have been 
excluded at the y-axis limit of 150C. An additional copy of C with a complete y-axis is shown 
in Supplemental Figure 4 D) By 48 hours there is a trend towards decreased mnID with 
increasing doses of tunicamycin. 
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Figure 21 shows a trend towards decreased survival in sMN cultures with increasing doses of 
tunicamycin which is apparent at 48 hours but not 24 hours, regardless of the analysis method 
used. The variability of the results denoted by the error bars can to some extent be addressed 
by including platedown in the statistical modelling of this data as described previously.  
 
Statistical analysis (Table 18) demonstrates an increasing dose of tunicamycin decreases sMN 
survival. This effect is statistically significant 48 hours after tunicamycin administration but 
not at 24 hours (α = 0.05).  
Independent 
Variable 
Coefficient Standard Error T value Likelihood 
ratio test 
24h survival -0.4824 0.2630 -1.834 P = 0.06863 
24h mnID -0.235 0.646 -0.433 P =  0.6648 
48h survival -1.0575 0.4063 -2.603 P = 0.01043 
48h mnID -1.2850 0.4805 -2.674 P = 0.008024 
Table 18: Output from four mixed linear regression models for the independent variables 
survival and mnID at 24 and 48h hours with dose and line as fixed effects and platedown 
as a random effect. Four additional models in which dose was removed as a covariate allowed 
assessment of hypothesis that survival would decrease with increasing tunicamycin dose. The 
likelihood ratio p values from this test are shown in the final column. 
 
The prior data analysis was important to ensure that any association between genotype and 
cell viability was not confounded by the aforementioned variables.  
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The presence of the C9ORF72 HRE does not increase decrease viability in sMN cultures 
treated with tunicamycin 
 
The hypothesis that the C9ORF72 mutation would decrease sMN survival at 48 hours after 
administration of tunicamycin, which induces ER stress and a UPR, was tested (Figure 22). 
 
Figure 22: Plots demonstrating that the decreased viability of sMNs with increasing doses 
of tunicamycin does not vary between control, C9ORF72 mutant and gene corrected lines. 
Controls are shown in green, C9ORF72 mutants in red and gene corrected controls in blue. 
Points denote the mean and error bars the 95% CI. The top row of plots shows the percentage 
of neurons that survived to 24 (A) and 48 (B) hours as determined by manual cell tracking. As 
in related Figure 21 survival can be seen to decrease between the 24 (A) and 48 hour (B) 
assessments. The bottom row of plots shows the relationship between mean normalised 
integrated density (mnID), a survival proxy, and tunicamycin dose. In contrast to percentage 
survival, the mnID does not decrease significantly between 24 (C) and 48 hours (D). The 
addition of calcein AM prior to imaging means the mnID of viable cells will remain constant 
or increase. With both analysis protocols the trend towards decreased survival with increasing 
doses of tunicamycin can again be seen at 48 hours (B and D) mirroring the result observed 
in Figure 21 where the responses of individual lines were assessed. There does not appear to 
be a clear difference in the response of any one genotype though the data cannot be displayed 
in its full dimensionality. Statistical modelling of the effect of genotype is shown in Table 19. 
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Independent 
Variable 
Genotype Coefficient Standard 
Error 
T value Likelihood 
ratio test 
24h survival Mutant 1.1734 2.3924 0.490 0.4524 
Corrected -1.6582 2.4727 -0.671 
24h mnID Mutant 21.795 6.343 3.436 0.002362 
Corrected 10.332 6.378 1.620 
48h survival Mutant 1.4287 3.7039 0.386 0.8579 
Corrected -0.3842 3.8239 -0.100 
48h mnID Mutant 4.5033 4.7186 0.954 0.2314 
Corrected  -2.1858 4.7444 -0.461 
Table 19: Output from four mixed linear regression models for the independent variables 
survival and mnID at 24 and 48h hours with dose as a fixed effect and platedown as a 
random effect. Four additional models in which genotype was removed as a factor allowed 
assessment of hypothesis that survival would decrease with increasing tunicamycin dose. The 
likelihood ratio p values from this test are shown in the final column. 
 
The visual data, the absence of negative correlations in C9ORF72 mutant lines in mixed linear 
regression modelling and insignificant likelihood ratios test suggest that the C9ORF72 
mutation does not result in decreased viability in response to tunicamycin relative to controls.  
 
Variability between individual cell lines is important to consider given the heterogeneity 
among lines demonstrated already in this work. Further investigation showed the increased 
survival in C9ORF72 mutants at 24 hours following tunicamycin determined by mnID to be 
heterogeneous. Of the three C9ORF72 mutant lines, two showed increased survival with 
coefficients of 41.9863 and 14.4327. The third line showed decreased survival with a coefficient 
of –22.3029. Further methodological and statistical parameters will have to be considered. 
 
It is concluded that the C9ORF72 HRE does not make three week sMNs more vulnerable to 
death following tunicamycin up to 48 hours following administration. 
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Insoluble TDP-43 is present in TARDBP mutant and corrected lines but not in 
C9ORF72 HRE carriers or controls  
 
TDP-43 pathology is evident in most cases of MND and is of relevance in C9-MND because it 
correlates well with neurodegeneration unlike DPR proteins (MacKenzie et al. 2013). 
Tunicamycin has also been demonstrated to lead to cytoplasmic TDP-43 inclusions in rodent 
slice cultures (Leggett et al. 2012). 
 
As C9-MND is also associated with TDP-43 pathology we sought to assess the TDP-43 status 
of these lines. Initially, experiments were performed on TARDBP mutant lines as a positive 
control to optimise the technique. 
 
Soluble and insoluble protein fractions were probed for TDP-43 from three-week-old sMN 
cultures (Figure 23). 
 
 
Figure 23: G298S-1 and gene corrected partners show increased expression of ~58kDa, 
~35kDa and ~25kDa TDP-43 products thought to be pathological from previous studies. 
Left: Western blot for TDP-43 in a TARDBPG298S mutant, gene corrected and control lines. 
Upper black horizontal bars indicate whether protein samples were derived from the soluble 
or insoluble (urea) fractions. A protein ladder has been marked on in pen (far left column). 
Calnexin has been used as a housekeeper. Note that an overexposed image has been presented 
to demonstrate all products identified. Where semi-quantitative densitometry has been 
performed Western blots analysed were insured to have grey values < 255. Right: Coomassie 
blue gel (greyscale) showing comparable protein loading for insoluble fraction samples which 
Western Blot Coomassie 
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cannot be normalised using a housekeeper. The samples are flanked on either side by protein 
ladders which have also taken up the Coomassie dye. 
 
Physiological TDP-43 at 43kDa was observed in control, TARDBPG298S and gene corrected lines 
in both soluble (n = 1) and insoluble protein fractions (n = 2). When levels of the 43kDa TDP-
43 in the soluble fraction have been normalised to a calnexin housekeeper to normalised for 
loading (Figure 24). 
 
Figure 24: Normalised abundance of TDP-43 to a calnexin housekeeper in the soluble 
fraction of three-week-old sMN cultures. n = 1. Replication is required before interpretation. 
 
A ~58kDa protein was observed in the soluble fraction only. The abundance of the ~58kDa 
product is lower in the control line when intensity is normalised to the calnexin housekeeper 
(Figure 25), however, a higher sample size is required to validate these findings. 
 
 
Figure 25: Normalised abundance of the 58kDa TDP-43 product to a calnexin housekeeper 
in the soluble fraction of three-week-old sMN cultures. n = 1. 
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While repetition and additional control lines are required this 58kDa product has been 
previously reported to represent phosphorylated TDP-43. Hyperphosphorylation of TDP-43 
is a pathological hallmark of MND and the 58kDa product is more abundant in G298S-1 and 
its gene corrected partners which mirrors pathology with respect to truncated TDP-43. 
 
G298S-1 and gene corrected partners showed additional products in the insoluble fraction at 
~35kDa and ~25kDa (Figure 23) and this was validated upon replication (n = 2). To a much 
lesser degree, some amount of the ~35kDa product is also present in the soluble fraction of a 
control line. Replication validated the presence of these products in the insoluble fraction of 
G298S-1 and G298S-Δ1 but provided no evidence of these products in controls. All the 
fragments described have also be observed in a TARDBPM337V mutant (data not shown). Gene 
correction does not abolish these pathological truncated TDP-43 products.  
 
Having demonstrated the ability to detect TDP-43 pathology TARDBP lines, the same 
experiments were repeated on lines harbouring the C9ORF72 HRE. The TDP-43 levels in the 
soluble fraction of control, C9ORF72 mutants and corrected lines were assessed normalised to 
the housekeeper protein - calnexin (Figure 26). G298S-1 was used as a positive control. Data 
from a single experiment did not show any relationship between soluble TDP-43 levels and 
genotype (n = 1). 
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Figure 26 Preliminary data suggests TDP-43 abundance in the soluble fraction varies 
between lines but is not associated with genotype.  Top: Western blot for TDP-43 and 
calnexin in the soluble protein fraction from three-week-old sMN cultures. n = 1 for all 
samples. Bottom: The density of the 43kDa band was normalised to that of the calnexin 
housekeeper and is expressed as a ratio on the y-axis. Further replication is required before 
conclusions can be drawn however the heterogeneity among C9ORF72 mutant lines would 
seem to indicate the abundance of soluble TDP-43 does not alter in lines carrying the C9ORF72 
HRE.  
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In the insoluble fraction of the C9ORF72 lines a small quantity of ~43kDa product was 
observed (n = 2). The G298S-1 positive control showed the expected products at ~35kDa and 
~25kDa as expected which were not evident in C9ORF72 mutants or gene corrected controls 




Figure 27: C9ORF72 mutant sMNs cultures at three weeks do show truncated TDP-43 
products in the insoluble protein fraction. Left: Western blot showing control, C9ORF72 
mutant and gene corrected insoluble protein samples with a G298S-1 positive control. Images 
have been subject to processing in an attempt to reveal low-intensity fragments. In all lines 
TDP-43 can be seen at its expected mass. Addition products are visible at ~35kDa and ~25kDa 
in the G298S-1 line. Right: Coomassie stained membrane showing protein loading. 
 
Nuclear evacuation of TDP-43 has been described in human tissue from patients with MND 
and FTD (Arai et al. 2006; Neumann et al. 2006). Work from rodent primary neuronal cultures 
has suggested nuclear evacuation of TDP-43 is a better indicator of impending cell death than 
cytoplasmic aggregations (Barmada et al. 2010). 
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After quantifying TDP-43 expression the next step was to use immunocytochemistry to 
investigate TDP-43 mislocalisation – another hallmark of MND pathology. On examination of 
control (n = 2), C9ORF72 mutant (n = 6) and gene corrected (n= 5) lines, there was no evidence 
of aggregation or nuclear evacuation. Figure 28 shows a representative image. 
 
 
Figure 28: Representative image of ICC for TDP-43 and tau with the nuclear dye DAPI 
showing homogenous nucleocytoplasmic distribution of TDP-43. Representative images 
from three week old sMN cultures (coverslip) imaged at x63. Left column: Image showing all 
channels: tau (red), TDP-43 (green) and DAPI (blue). Middle column: DAPI signal alone. Right 
column: TDP-43 signal alone.  
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TARDBP Genotyping 
 
The identification of insoluble TDP-43 in the gene corrected lines was unexpected. To confirm 
the identity of the lines DNA was purified and PCR performed generating a 452bp amplicon 
of exon 6 spanning the mutation site. Confirmation of successful amplification was obtained 
by gel electrophoresis before the samples were sent for Sanger Sequencing (Figure 29).  
 
Figure 29: Genotyping of G298S-Δ1. A) Sanger Sequence of G298S-Δ1. B) Sequence alignment 
of the wild-type (upper) and G298S-Δ1 sample were assessed using the EMBOSS local 
alignment tool (Water). Codon 298 does not vary refuting the hypothesis that the insoluble 
TDP-43 observed in this line was the result of the line not having a control identity. Silent 
mutations inserted at the time of gene-correction in codons 304 and 305 are also detected 
confirming the line has been gene corrected and is not a wild-type control. C) The silent 
mutation introduces a BsaJI cut site. 
 
The above evidence suggests that both G298S-1 and its gene corrected controls show evidence 
of TDP-43 pathology. This throws into question the relationship between TARDBP mutations 
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Chapter 3 – Results Notes 
 
A – On reflection, two control lines should have been included in each experiment. One 
would have been able to serve as a constant for normalisation while the addition of the 
second would allow the variability of protein expression in control lines to be expressed. 
Cell culture logistics though and a lack of experience and forward thinking with respect to 
data analysis on my behalf precluded this. 
B – This data set is large and noisy but the variation between platedown is prominent in a 
number of matched subsamples. 
C – Failure to limit the y-axis would have resulted in further compression of the majority of 
datasets making the visualisation of results more challenging. 
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Chapter 4: Discussion 
 
A cellular model of MND has been used to investigate the role of the C9ORF72 HRE on sMNs. 
The inclusion of both healthy controls and isogenic controls for each of the three C9 lines 
studied allows several different types of conclusion to be made. A hypothetical pathological 
phenotype is considered in Table 20. Possible distributions of this phenotype among control, 
mutant and corrected lines are considered as well as the inferences which can be made from 
such distributions. 
Control Mutant Corrected Inference 
Absent Present Absent The phenotype is a function of the C9ORF72 HRE 
specifically 
Absent Present Present The phenotype is a function of diseased lines 
independent of the C9ORF72 mutation 
Absent Absent Absent The phenotype is not associated with C9-MND in 
this study 
Table 20:  Table showing the distribution of a hypothetical pathological phenotype among 
control, mutant and gene corrected lines with an inference about the phenotype based on 
this distribution. The phenotype in each case is described as present or absent. 
 
With these distinctions possible, it was sought to investigate the role of the UPR in C9-MND 
and specifically the role of the C9ORF72 HRE. 
 
Transcriptomic data identified the C9ORF72 HRE perturbs expression of a 
number of transcripts many of are associated with pathways already 
associated with MND 
  
RNAseq data was used to identify transcripts in which gene expression was significantly 
altered by the C9ORF72 mutation. Whole transcriptome profiling was performed on three-
week-old sMNs derived from for 2 independent healthy controls, 2 C9-MND cases and 1 
isogenic control line. Differentially expressed genes were identified by following criteria: 
1. Genes must have significant differential expression in both independent mutant 
C9ORF72 lines (p < 0.05) when compared to independent control lines 
2. There must be a significant difference between C9-1 and C9-1 (p < 0.05) 
3. There must be no significant difference observed between C9-1 and controls (p > 
0.05). 
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Assessment of protein class using PANTHER showed enrichment for many pathways which 
have already been implicated in C9-MND and more broadly MND as a whole. These proteins 
map to pathways involved in RNA metabolism, excitotoxicity, nucleocytoplasmic shuttling, 
axonal transport, metabolism, oxidative stress and the UPR. This is a valuable dataset and 
though it shall not be considered further here it will provide a surplus of candidates for further 
investigation. With a decrease in price, transcriptomic datasets are becoming more common 
and a number of such datasets of relevance to the study of MND have been made available 
online (Ferraiuolo et al. 2007; de Oliveira et al. 2013; Donnelly et al. 2013; Groen et al. 2013; 
Heath et al. 2013; Maximino et al. 2014; Aronica et al. 2015; Noristani et al. 2015; Patin et al. 
2016; Riva et al. 2016; Wang et al. 2017). 
 
In the future, it would be interesting to compare these datasets. Though often protocols, 
species and timepoints vary substantially if experiments have been independently well 
performed it may prove an excellent resource for generating hypotheses in an economically 
efficient manner.  
 
Of the three candidate genes examined, only HSPB8 mRNA upregulation was 
validated 
 
Three candidate genes from the RNAseq findings involved in the UPR were selected for 
validation by qPCR. 
 
HSP90B1 has been implicated in many cellular functions but of particular relevance here is 
the role it plays as an ER chaperone. Its role seems to have been most heavily studied in 
immunological protein homeostasis but recently it has been shown to play a role in ERAD (Di 
et al. 2016). HSP90B1 status does not seem to have been described in MND but has been 
implicated in another of the motor neuron diseases – SMA.  SMA is caused by mutations in 
the SMN1 gene which codes for survival motor neuron (SMN) protein (Lorson et al. 1999).  
HSP90B1 is downregulated in cellular models of SMN knockout (KO) (Wu et al. 2011). 
HSP90B1 mutations have not been associated with any human disease. Failure to validate this 
RNAseq hit is disappointing given it had one of the greatest effect sizes. The transcript does 
appear to be significantly upregulated in C9-3 but not in C9-1 (Figure 10). This provides the 
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first evidence presented of heterogeneity among C9ORF72 mutants which will be discussed 
later.  
 
HSPB8 has been previously implicated in MN pathology. Two diseases, both of which affect 
motor neurons, have been attributed to HSPB8 mutations: hereditary distal motor neuropathy 
type IIA (Irobi et al. 2010) and hereditary motor and sensory neuropathy type 2L (Tang et al. 
2005). HSPB8 known to have chaperone activity and has recently been reported to play a role 
in combating the accumulation of truncated TDP-43 products (Crippa et al. 2016). Work in 
primary neuronal cultures has shown that neurons subject to lentiviral transfection with 
mutant HSPB8 show evidence of neurite degeneration (Irobi et al. 2010); specifically, a 
decreased number of neurites per cell and decreased neurite length. This was not seen in cells 
transfected with wild-type HSPB8 and the phenotype was most marked in motor neurons, 
with minor involvement of sensory neurons and sparing of cortical neurons.  In the current 
study, upregulation of HSPB8 expression is demonstrated in C9ORF72 mutants (Figure 11) 
with restoration to within normal limits in gene corrected controls suggesting the 
upregulation is a direct result of the C9ORF72 HRE. This could result from several 
mechanisms including transcriptional changes caused by pathological RNA foci or as a 
response to DPR protein aggregates within these cells.  Considering the absence of insoluble 
TDP-43 pathology in these lines, the presence of DPR proteins and RNA foci and restoration 
of the phenotype in gene corrected controls, it is speculated that HSPB8 upregulation may be 
independent of TDP-43. It could be argued though that TDP-43 pathology is driving the 
upregulation of HSPB8 in a response which will eventually become decompensated leading 
to aggregation and neuronal death. This possibility could be investigated by examining the 
C9ORF72 lines at later time points. If TDP-43 pathology can be identified at later 
developmental stages it could be hypothesised that HSPB8 KO would lead to earlier onset 
TDP-43 pathology. It should be remembered that there is increasing evidence in 
neurodegenerative diseases associated with protein aggregates that soluble forms of the 
proteins that cause toxicity (Haass and Selkoe 2007). 
 
XPO1 was of interest because of its role in nucleocytoplasmic shuttling (Fornerod et al. 1997). 
It functions in the export of over 200 proteins from the nucleus (Fu et al. 2013) and evidence 
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has implicated nucleocytoplasmic transport as a potential driver of pathophysiology in 
C9ORF72 HRE disease recently reviewed by Zhang et al. (Zhang et al. 2015). No change in 
XPO1 levels was demonstrated in C9-MND lines (Figure 12). While, to our knowledge, no 
previous reports of alterations in XPO1 status have been associated with C9-MND, XPO1 
levels have been shown to be associated with those of TDP-43. In a cellular  TDP-43 KO model 
increased levels of XPO1 have been demonstrated (Štalekar et al. 2015). It may be that it is too 
early to see changes associated with XPO1 which may come with more advanced TDP-43 
pathology. 
 
C9ORF72 mutant sMNs did not show evidence of a constitutively active 
unfolded protein response 
 
Given the link between HSPB8, TDP-43 and C9ORF72, the status of the UPR in C9ORF72 
mutant sMNs was investigated. Previous work by Dafinca et al. has demonstrated the 
presence of ER stress granules in iPSC-derived sMNs between two and four weeks post 
platedown (Dafinca et al. 2016) so it was hypothesised that increased ER stress sensor 
activation would be observed in these lines. The UPR was investigated in three-week-old 
C9ORF72 mutant sMNs by studying the three ER stress sensors – IRE1, PERK and ATF6.  
 
IRE1 activation was assessed by looking downstream at XBP1 splicing. The ratio between 
spliced and unspliced XBP1 transcripts was used as an indicator of ER stress and IRE1 
activation. The spliced XBP1 transcript was not observed in any cell line examined in basal 
conditions (control, C9ORF72 mutant, C9ORF72 gene corrected and TARDBPG298S gene 
corrected) (Figure 14). To determine if a dynamic response to tunicamycin might be observed, 
cells treated with tunicamycin (5ug/mL) or DMSO as a control were subject to the same 
analysis. XBP1 transcript splicing was observed in tunicamycin-treated cells and not in the 
DMSO control group but no differences in response to tunicamycin were observed in any cell 
line tested (Figure 15). In MND disease and Huntington’s disease, XBP1 deficiency appears to 
be neuroprotective (Hetz et al. 2009; Vidal et al. 2012). In a transgenic rat model (Camk2α-tTA) 
progressive depletion of both full length and spliced XBP1 protein have been demonstrated 
with increasing TDP-43 pathology in neurons. The  XBP1 response to disease was cell type 
specific with upregulation in reactive microglia and not in reactive astrocytes (Tong et al. 
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2012). This XBP1 depletion was found before the formation of ubiquitin inclusion bodies or 
Golgi fragmentation. If TDP-43 pathology is identified in C9ORF72 mutant sMNs at later time 
points in the future it would be interesting to then re-examine the status of XBP1 splicing in 
these lines. 
 
PERK upregulation has previously been demonstrated in post-mortem tissue from patients 
with MND (Atkin et al. 2008) and PERK overexpression has been shown to reduce tau 
pathology associated with progressive supranuclear palsy (PSP) (Bruch et al. 2017). In the 
SOD1G85R mouse model of MND heterozygotes for PERK KO showed earlier disease onset and 
a decreased lifespan (Wang et al. 2011). Together, these results can be used to hypothesise that 
the upregulation of total PERK seen in end-stage MND may represent a decompensated 
neuroprotective response. Here, there is no evidence of PERK upregulation under basal 
conditions in C9ORF72 mutants in three-week-old sMNs (Figure 16). There is, however, when 
isogeneic pairs are considered, a trend towards increased PERK expression in cells which have 
been treated with tunicamycin associated with the C9ORF72 HRE (Figure 17). Variation 
among this response in the two control lines examined though was high so this may represent 
natural variation and repetition is required before conclusions can be made. Nevertheless, this 
trend towards increased total PERK as a result of the C9ORF72 HRE was observed in both 
C9ORF72 mutant lines examined (C9-1 and C9-2). 
 
AFT6, following ER stress, is subject to regulated intramembrane proteolysis with cleaved 
fragments translocating to the nucleus to modify gene expression (Haze et al. 1999). The 
greatest alteration in ATF6 observed in these iPSC-derived sMN lines was markedly increased 
production of a 37kDa spliced fraction of ATF6 in TARDBPG298S mutants (Figure 18). This 
protein fragment was observed in both mutant and gene corrected lines. This suggests that 
the individual from whom these lines were derived was prone to ER stress at a cellular level 
in a manner independent of the disease mutation. This is in keeping with the finding of 
TARDBPG2983-independent insoluble pathogenic TDP-43 in the gene-corrected lines of this 
individual (Figure 23). 
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In C9ORF72 mutants the C9-1 isogenic pair does not show any alteration in the ratio of full 
length to cleaved ATF6, either constitutively, or following treatment with tunicamycin 
(Figures 18 and 19). In comparison, C9-2 showed an HRE-dependent increase in ATF6 
cleavage basally and an exaggerated response after tunicamycin treatment which is only 
partly explained by the C9ORF72 HRE. This requires reconciliation with the evidence that 
even in C9-2 under basal conditions the ratio of full length to cleaved ATF6 is comparable to 
that of the control line. Further repetition of this experiment with the addition of another 
control line will aid interpretation. If divergence of values is demonstrated in C9-1 and it’s 
isogenic control it could be postulated that an environmental variable is driving this 
divergence and the increased ATF6 cleavage in C9-2 cannot be attributed to the C9ORF72 HRE 
in its entirety. If, however, the values remain consistent for C9-1 we might argue that gene 
correction is proving effective in reducing interline variability and in C9-2 the HRE is driving 
increased ATF6 cleavage. This suggests an additional factor in C9-2 modifies the response to 
the HRE. This could be a ‘juxtamutation’ factor (or factors) in concert with the C9ORF72 HRE 
in the C9-2 genome have led to a phenotype of increased ATF6 cleavage or alternatively, a 
difference in the HRE itself, such as length, leads to different phenotypes. The former 
hypothesis seems more likely, however, it should be noted that the repeat length of C9-2 is 
known to be longer than that of C9-1. In the case of basal ATF6 cleavage, it would seem that 
this observation could not account alone for the individuals’ MND because the healthy control 
also shows a similar relative abundance of 37kDa ATF6. The situation following treatment 
with tunicamycin is different again. This time, C9-2 shows a markedly increased upregulation 
of 37kDa ATF6 in response to tunicamycin in excess of that of the control line. An important 
limitation of the dataset at present is that the control line is not the same as that used to 
investigate the constitutional activity of ATF6; this will be corrected in future experiments. 
 
Convergence of pathways implicated in MN degeneration in MND is evidenced by 
considering the interaction between excitotoxicity and the unfolded protein response. 
Evidence has been acquired in cellular models of SOD1 mutations showing XBP1 splicing 
increases with MN electrical activity (Wang et al. 2017). Interestingly, this relationship is 
bidirectional and induction of XBP1 splicing with dichlorodiphenyltrichloroethane (DDT) 
increased the firing rate of MNs.  
 
87 | P a g e  
 
MScR The University of Edinburgh 2017 
C9ORF72 HRE sMNs are not more vulnerable to tunicamycin than controls 
 
Ultimately, the end result of pathology in MND is the death of MNs. Thus, after the above 
mechanistic investigation, the viability of C9ORF72 sMNs in response to the ER stressor 
tunicamycin was undertaken.  
 
Data from the two analysis approaches applied to survival data both suggest that the 
C9ORF72 HRE in sMNs does not confer susceptibility to death following tunicamycin-
induced ER stress. This finding contrasts with a previous report in the literature (Haeusler et 
al. 2014). This study shows the increased vulnerability of iPSC-derived motor neurons to 
tunicamycin determined by increased uptake of the dye propidium iodide (PI) which they 
present in their Extended Data Figure 9. In an attempt to understand this discrepancy the 
methods used by Haeusler et al. are compared to the manual cell tracking survival analysis 
presented here. The manual cell tracking survival analysis is compared because it is more 
technically similar to the method used by Haeusler.  
 
PI cannot cross intact cell membranes so is taken up by compromised cells providing a means 
to assess viability. Calcein AM also reports primarily on membrane integrity as active AM 
metabolite cannot escape from the cell across intact membranes. Haeusler et al. show data 
from one C9ORF72 control line and one C9ORF72 HRE line. Both these lines were 
independently differentiated twice compared to the four-plus number of replicates here. MNs 
were differentiated using a different protocol and grown using different surfaces and coatings 
(poly-L-lysine and laminin on glass verses LMF on plastic). Anecdotally, the Chandran lab 
has observed diverge in phenotype based on the type of coating used (LMF verses laminin) 
with resistance to a ‘pathological’ phenotype on LMF as we used here. This could provide 
some explanation for the divergence. Though not explicitly stated, based on the timing of 
other experiments in the paper and the previous work of the lab it seems feasible experiments 
were conducted on MNs around 50 days old (slightly older than the 37-day old neurons used 
here). The doses of tunicamycin are reported as varying from 0.1μM to 3μM. Tunicamycin is 
a mixture of homologous compounds with a variable atomic mass.  In the absence of more 
information, we shall assume the four major homologs are present in equal quantities giving 
an average atomic mass of 840.25. This equates to 84.025μg to 2.52075mg per litre (Table 21). 
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This thesis 1 10 
Haeusler et al. 2014 0.084025 2.52075 
Table 21: Comparison of tunicamycin doses used by Gane and Haeusler. 
 
The mean number of cells sampled per condition was 59.8 by Haeusler in contrast to 48.5 in 
the manual cell tracking experiments described here. The effect size of the survival deficit is 
large. 
 
Given the greater number of C9ORF72 mutant lines and the increased number of technical 
replicates presented here the work of Haeusler at al. does not decrease my confidence in the 
concluding that iPSC-derived MNs from C9-MND patients do not have increased 
vulnerability to ER stress. I would speculate the differences observed most likely be due to 
line variation independent of C9ORF72 mutation status which could be missed using only one 
iPSC line or, alternatively, an effect of ageing. MND is an adult-onset disease and the older 
MN cultures of Haeusler at al. have an advantage in that we might hope, for the purposes of 
accurate disease modelling, not to observe these pathophysiological phenomena in ‘young’ 
neurons. Having said this, the difference in age is not large (though important developmental 
events do happen over a short space of time) and with the higher doses used here we might 
hope to observe a phenotype in younger cells because of the greater degree of stress applied. 
 
Fitting abnormal protein homeostasis into the bigger picture of MND 
 
A summary of key findings is shown in Table 22. With the analysis of UPR stress sensors, 
tunicamycin survival assay, TDP-43 and DPR status of control, mutant and gene corrected 
lines we can consider how protein homeostasis may fit into the bigger picture of MND. The 
picture is complex and I do not believe given the available evidence a strong conclusion can 
be made regarding the relationship between the C9ORF72 HRE and UPR – repetition of all 
the biochemical experiments is required with the addition of lines that were missing so that 
data on all eight lines are available. This is essential because there is heterogeneity among the 
C9ORF72 mutants. 
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C9-1 shows alterations in of HSPB8 transcript and PERK function, but not HSP90B1 or ATF6. 
C9-2 shows evidence not only of ER-stress as determined by PERK and ATF6 cleavage. Data 
regarding the HSP90B1 status of C9-2 has not been acquired – this shall be sought. C9-3 shows 
upregulation of HSP90B1 and PERK. Of the three C9ORF72 mutants, C9-2 was the only one 
not to show a pro-survival phenotype at 24h in the mnID survival analysis. C9-3 showed 
evidence of HSPB8 and HSP90B1 upregulation with PERK changes but data regarding the 
ATF6 data of this line is missing. This heterogeneity is in keeping with the hypothesis that 
MND is a multistep disease. Major genetic risk factors alone are insufficient to cause the 
disease – as evidenced by the fact that a C9ORF72 HRE is present around 0.1% of the healthy 
population (Murphy et al. 2017).  
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C9-1 Normal Upregulated Normal Exaggerated 
response to 
tunicamycin 
Normal Normal May delay 
death 
None detected Increased 
C9-Δ1 Normal Normal Normal Rescue Normal Normal No deficit None detected Rescued 









Normal No deficit None detected - 
C9-Δ2 - - - Rescue Partial rescue Normal No deficit None detected - 
C9-3 Upregulated Upregulated Normal Exaggerated 
response to 
tunicamycin 
- Normal May delay 
death 
None detected Increased 
C9-Δ3 - - - Rescue - Normal No deficit None detected - 
G298S - - - No basal 
stress 
Basal stress Normal under 
basal 
conditions 
- Present - 
G298S-Δ1 - - - No basal 
stress 
Basal stress - - Present - 
G298S-Δ1 - - - No basal 
stress 
Basal stress - - Present - 
M337V - - - - - - - Present - 
Table 22: Summary of experimental findings. Factors not yet assessed are denoted by a hyphen. Data on DPR protein aggregates were obtained 
by Dr B. T. Selvaraj and is shown in Supplemental Figure 6. 
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Heterogeneity in C9-MND iPSC-derived sMN is also evident in the literature. Dafinca 
et al. have recently reported abnormalities in ER calcium handling and stress granule 
formation (Dafinca et al. 2016). Using six lines derived from three patients with C9-
MND, it was demonstrated that on treatment with thapsigargin C9-MND lines retain 
Ca2+. Elevated Ca2+ within the ER has been associated with ER stress sensor activation 
and the authors go on to investigate the level of GRP78. Of the three lines examined, 
only one shows significantly upregulated GRP78 supporting the findings here of 
heterogeneity amount C9-MND lines. Interestingly, the pair of lines associated with 
the greatest retention of ER Ca2+ was not the pair in which GRP78 was significantly 
upregulated. It is also reassuring to note that in this data values of GRP78 normalised 
to β-actin vary little between lines derived from the same patient, suggesting this 
heterogeneity is a genuine function the patient genomes and not an artefact of 
reprogramming or cell culture. 
 
These results lend further support for a multistep hypothesis of MND. Such a model 
may explain clinical phenomena such as the clinical variability of MND within 
families (Siddique et al. 1991) and marked alterations in genetic contributions in 
different populations (Veldink 2017), as well as differences in cellular 
pathophysiology between patients as is described here. Studying these diseases in 
models with a limited number of control or disease lines may result in the generation 
of false dichotomies when in reality different individuals have MND because of 
different ‘hits’ which converge to cause MND. It seems likely because of the features 
shared among motor neuron diseases that these hits converge in a pathway or 
combination of pathways uniquely important to MNs. A simplified model is shown 
in Figure 30. 
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Figure 30: Model hypothesis by which multiple hits result in the development of 
MND, FTD or both in an individual. From left to right graphics show cortical 
neurons, motor neurons and muscle. Degeneration of motor neurons results in MND. 
Degeneration of cortical neurons results in FTD. The neuronal viability is shown in 
colour with degeneration from green (healthy) through orange to red (non-viable). 
Hits 1 to 4 are added in series but in this simplified scenario could occur in any order. 
The order may be important in vivo, for example, KO of a DNA repair gene A followed 
by subsequent mutagenesis of gene B may be more detrimental than if gene B was 
damaged and subject to DNA repair mechanisms before KO of DNA repair gene A. 
The timing of these hits is also important. For hits acquired in a large number of 
somatic cells, it is most conceivable that DNA damage occurred early in development 
in a pluripotent cell affecting all subsequent offspring (bottom right). Age-related 
factors or subsequent environmental hits transform this developmental susceptibility 
to adult-onset disease. An alternative scenario is that hits are acquired throughout life 
but this requires a mechanism by which a neuronal subpopulation can become 
selectively vulnerable. A major issue when seeking to identify necessary and 
sufficient hits is biological redundancy – demonstrated here by the lack of discernible 
effect on the system following Hit 1. Assuming Hit 1 is genetic - whole genome 
sequencing (WGS) of the system at this time though may lead to the identification of 
evidence a pathological hit has been obtained in the absence of a phenotype. 
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The data obtained from the TARDBPG298S line similarly suggests a complex disease 
process with at least some ‘classical’ features of MND including ER stress (as 
determined by increased ATF6 cleavage) and the presence of insoluble TDP-43  are 
independent of the G298S mutation. The ultimate test of the sufficiency of the G298S 
mutation would be to insert it into a healthy control line and investigate for signs of 
pathology. This could be achieved using a strategy very similar to the TARDBPM337V 
gene correction described in Chapter 5. If the pathological aspects of MND are again 
not evident it will suggest that something beyond the G298S mutation is producing a 
pathological signature. 
 
Deficits in how cells handle ER stress may constitute a possible ‘hit’ in the multistep 
process that is MND and these hits may fall within different components of the UPR 
leading to heterogeneity in patient lines.  With this data, we are not in a position to 
say whether a hit to the UPR is necessary for MND to develop. This would be an 
interesting question to address in the future. 
 
The power of studying a multistep disease with gene editing 
 
Genetic engineering of mammalian cell lines offers immense potential in the 
dissection of diseases with complex genetics. The introduction of the CRISPR/Cas 
system for genetic engineering has already lead to publications in the field of MND 
using gene corrected control lines (Kiskinis et al. 2014; Wang et al. 2017). It is 
interesting that RNAseq experiments performed on these datasets so far have 
compared mutant cells lines to gene corrected controls only. As described above, 
while this lends power to the study of the specific effect of the mutation information 
is also lost – any other alterations in the ‘juxtamutation’ genome which predisposed 
the individuals to develop this complex genetic disease. These concerns are arguably 
greater for mutations like the C9ORF72, which has been associated with a number of 
different phenotypes. 
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Limitations 
 
The limitations of this research can be considered as specific limitations of this work 




The major limitation of this work is the limited number of times certain experiments 
have been independently repeated. Until this is achieved, confident conclusions as to 
the UPR phenotype of these lines is impossible. 
 
It will also be necessary to confirm PERK activation by examination of 
phosphorylation or investigation of downstream targets. The status of phospho-
PERK in MND patients has not yet been reported in the literature. The fact we observe 
an increase in total PERK on administration though is a positive sign that a functional 
readout is being obtained.  It should also be remembered that ER stress which has 
been simulated with tunicamycin here whereas ER stress in human C9-MND is likely 
to result from a number of different factors. 
 
Statistical limitations regarding the assumptions for mixed linear regression 
modelling in the survival analysis also require consideration. Of these, right-





The isolated study of sMNs has its limitations. Non-cell autonomous effects are 
increasingly being reported with the contributions of glial cells to the 
pathophysiology of MND increasingly recognised (Ilieva et al. 2009). These cultures 
lack cellular input from cortical neurons and cannot provide output to muscle.  A lack 
of cortical input limits our ability to study the dying-forward hypothesis of MND 
which has recently been reviewed (Geevasinga et al. 2016). Briefly, the dying forward 
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hypothesis postulates that sMN death in MND results from dysfunction of upstream 
cortical neurons (Eisen et al. 1992). The key mechanism proposed currently for a 
dying-forward mechanism is excitotoxicity and since the publication of this review 
new evidence of upstream pathology has arisen. Unpublished observations by Dr B. 
T. Selvaraj et al. (in review) demonstrate AMPA-mediated excitotoxicity in C9-MND. 
This has not yet been demonstrated in a cortical-sMN co-culture model in vitro though 
without the addition of depolarising agents. The role of muscle in MND is also under 
investigation and advances have been made recently which allow investigation of 




In conclusion, the status of the UPR of sMNs has been found to vary across three 
different C9-MND patient lines and it has been demonstrated that C9ORF72 mutant 
neurons are not more vulnerable to tunicamycin-induced death in this system. 
Additionally, it is evident that specific arms of the UPR can be activated differentially. 
A common feature of all three lines was upregulation of HSPB8 transcript, known to 
play a role in the disassembly of protein aggregates, including TDP-43. TDP-43 
pathology, however, is not present in C9ORF72 mutant sMN cultures at this time 
though DPR protein inclusions are. Further replication is required before conclusions 
can be made regarding the status of individual ER stress sensor pathways. 
 
In contrast, there is evidence that sMNs derived from a patient with TARDBPG298S 
mutation show evidence of constitutive ER stress determined by ATF6 cleavage and 
insoluble TDP-43 pathology independent of the G298S mutation. 
 
Given the association between the C9ORF72 HRE and disruption to cell proteostasis, 
further dissection of these pathways will be of relevance to MND and other 
neurodegenerative conditions more broadly. These findings are in keeping with a 
multistep hypothesis of C9-MND. 
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Adult-onset ALS has been reported with the TARDBPM337V mutation (Tamaoka et al. 
2010). An adenine (A) to guanine (G) substitution at position 1009 in exon 6 of 
TARDBP results in codon 337 coding for valine instead of methionine. The Chandran 
lab has an iPSC line from an individual with ALS who carries the TARDBPM337V 
mutation. An isogenic control for this line has not yet been generated. To demonstrate 
an understanding of the gene editing process I outline a strategy here for the 
generation of a corrected cell line using the CRISPR-Cas9 system. During my time in 
the lab, I assisted in gene editing projects and some of these experiences are included 
as notes where relevant. 
 
In brief, the CRISPR-Cas9 system constitutes part of the bacterial acquired immune 
system (Barrangous et al. 2007). Clustered Regularly Interspaced Short Palindromic 
Repeats (CRISPR) interspaced with hypervariable sequences (protospacers) were 
identified following sequencing of the bacterial genome and were identified as 
structurally peculiar. It was not till later on that it was demonstrated that these 
hypervariable spacer sequences are derived from external nucleic acids such as those 
of bacteriophages (Barrangous et al. 2007). Three different types of CRISPR system 
have been described with the type II system now commonly used for gene editing in 
many species. The different CRISPR systems have different properties but the most 
commonly used system is derived from Streptococcus pyogenes in which the target 
sequence must precede 5’-NGG protospacer adjacent motif (PAM)  (Ran et al. 2013). 
The PAM sequence is specific to different CRISPR systems. 
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In its essence, the CRISPR-Cas9 system in Streptococcus pyogenes consists of three 
components: 
1. Cas9 – an RNA-guided nuclease which generates double-stranded breaks 
(DSBs) 
2. crRNA – a 20nt guide sequence preceding the PAM  which is complementary 
to the target sequence 
3. tracrRNA – a nucleic acid through which the crRNA interacts with Cas9 
 
Different genomic locations can be targeted by changing the sequence of the crRNA 
without modifying the other components. This feature gives the CRISPR-Cas9 system 
an advantage over its predecessors, zinc-finger nucleases (ZFNs) and transcription 
activator-like effector nucleases (TALENs), in which a nuclease domain is attached to 
a DNA-binding protein as it is much easier to design and produce the targeting 
crRNA sequence than it is to create customised DNA-binding proteins (Ran et al. 
2013). Furthermore, crRNA and tracrRNA sequences can be subcloned as a single 
construct termed a single guide RNA (sgRNA) (Jinek et al. 2012) or synthesised 
directly following annealing of oligonucleotides.  CRISPR-Cas9 genome targeting is, 
however, constrained in that sgRNAs must target 5’ to the specific PAM sequence – 
NGG for Streptococcus pyogenes. Practically, this poses little constraint because of the 
regular occurrence of these three nucleotide sequences throughout the genome. Cas9 
cuts ~3bp upstream of the PAM.  
 
The most simple form of gene editing using CRISPR-Cas9 requires the introduction 
of two constructs within the cell – the Cas9 and the sgRNA. Cas9 can be introduced 
either as a protein or as plasmid expressing Cas9 cDNA under a mammalian 
promoter. Although early protocols used Cas9-expressing plasmids to synthesis Cas9 
de novo more recent studies show more favourable kinetics with protein transfection. 
The reduced half-life of Cas9 following protein transfection compared to plasmid 
transfection has been reported to reduce off-target effects (Liang et al. 2015) with 
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comparable HDR frequency (Sentmanat and Miller)A. Introduction of Cas9 and 
sgRNA into a cell will result in the introduction of double-stranded DNA (dsDNA) 
breaks at target sites. Unmodified Cas9 cleaves DNA with blunt ends and DNA repair 
mechanisms within the cell then reconstitute cleaved DNA. 
  
When DSBs are introduced in DNA two principle repair pathways exist – non-
homologous end joining (NHEJ) or homology-directed repair (HDR) (Kanaar et al. 
2008). Of these, HDR is a more advanced process in which a homology repair 
template (HRT) informs the product of the DNA repair machinery. The editing of 
TARDBPM337V will require a strategy compatible with HDR. In cases where HDR is 
required the repair template can be introduced either in a plasmid or as single-
stranded oligodeoxynucleotides (ssODNs). ssODNs can be easily synthesised using 
the phosphoramidite method – the major constraint being the maximum length of an 
oligonucleotide that can be sequenced. In this project, a relatively short (<100bp) HRT 
is required and thus a ssODN repair template has been used. 
 
Briefly, NHEJ has found application for several functions. Some utility comes from 
the error-prone nature of NHEJ which can lead to random mutations including 
insertions, deletions (in-dels) at the site of DSB. This strategy has been used to create 
knockout (KO) models in which in-dels lead to the formation of truncated products 
through direct synthesis of a stop codon or more commonly shifting the reading 
frame. Pairs of sgRNAs have also been used to excise portions of genomes and this 
strategy was adopted for the generation of the C9ORF72 gene corrected controls (see 
Methods). The factors that influence whether a cell undergoes NHEJ or HDR are of 
importance as in both cases the efficiency of genome editing in mammalian cells is 
low. Factors such as the type of nuclease, guide orientation, target locus and cell type 
all affect the efficiency of the various different gene editing pathways (Miyaoka et al. 
2016). Interestingly, the addition of non-homologous DNA during transfection 
increases in-del rate so even in genome editing strategies in which HDR is not 
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required it may be advisable to include additional oligonucleotides in the transfection 
mix (Richardson et al. 2016). 
 
An overview of a strategy by which the TARDBPM337V correction could be performed 




Homology-directed repair (HDR) is required to correct the A → G missense mutation 
at position c1009 of TARDBP resulting in a substitution of methionine to valine at 
codon 337 (pM337V). The mutation lies within exon 6 which can be amplified via PCR 
as described in Methods. This amplified region can then be subject to Sanger 
sequencing (Source Biosciences). Sequencing the target genome served both to 
confirm the nature of the A to G missense mutation at codon 337 as well as identifying 
variants in the surrounding sequences. Failure to identify such variants could reduce 
the efficiency of targeting constructs and was thus preferable to relying on reference 
sequences. 
 
An online tool by the Zhang lab allows identification of possible crRNA sequences 
(http://crispr.mit.edu/). The advantage of this approach over manual identification of 
PAM sites (5’-NGG-3’ in the case of Streptococcus pyogenes) near the mutation and 
gRNAs is that it allows rapid comparison of many guides with information on their 
likely off-target effects. If specificity cannot be achieved with a crRNA a nickase 
system can be considered. If a silent mutation can be introduced into the PAM this is 
ideal as these changes can be incorporated into the HRT to prevent targeting of the 
repair template by Cas9. These mutations must be silent as they will also be 
introduced to the target genome. If this is not the case silent mutations will need to 
be inserted into the region of the HRT corresponding to the seed region of the sgRNA 
– the 12 nucleotides 5’ of the PAM. With this in mind, the HRT can then be designed. 
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The HRT must not be targeted by Cas9 so mutations must either be introduced to the 
PAM or seed as mentioned above, these mutations will be transferred to the target 
genome though so should be silent. In practice, this is easy to achieve because of 
redundancy in the amino acid code. More challenging is configuring these silent 
mutations so that a restriction enzyme cut site is created or destroyed allowing 
screening via restriction fragment length polymorphism (RFLP) analysis. Ideally, the 
banding pattern expected should be easy to resolve and interpret when used for RFLP 
screening. Synthesis of the HRT for this specific edit is reasonably straightforward as 
the short length of the HRT permits direct industrial synthesis.  Consideration must 
then be given to the delivery system. Cas9 is delivered as a protein here because of 
the associated benefit of reduction of off-target cutting and increased efficiency. The 
sgRNA here is synthesised by annealing together two oligonucleotides – the custom 
designed crRNA with an additional 3’ direct repeat sequence and the standard 
tracrRNA scaffold. The transfection will be carried out by nucleofection. Initially, the 
efficiency of sgRNA targeting should be assessed via the T7 endonuclease assay. If 
the cutting efficiency is low an alternative crRNA should be tried. If sufficient, the 
targeting experiment can be performed with Cas9, gRNA and HRT. Following 
transfection and recovery of iPSCs, cells are re-plated down at a low density in a 10cm 
dish to allow clonal selection. Following clonal selection colonies should be expanded 
and passaged with one sample used for screening, in this case using RFLP, and the 
other maintained so that in clones in which screening is promising cultures can be 
expanded and sequenced for confirmation.  
Construct Design 
 
A 452bp amplicon of TARDBP exon 6 of a TARDBPM337V line was sequenced as 
described in Methods. This served to both confirm the nature of the A to G missense 
mutation at codon 337 as well as identifying variants in the surrounding sequences. 
Failure to identify such variants could reduce the efficiency of targeting constructs 
and was thus preferable to relying on reference sequences. 
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PAM sites surrounding codon 337 were identified and are shown in yellow in Figure 
30. 
 
Figure 30: Figure showing PAM sites surrounding TARDBP codon 337. Codon 337 
is marked with a grey box. PAM (NGG) sites are shown in yellow. 
 
The closest possible PAM site at which a silent mutation could be introduced was 
over 30bp from codon 337. At this distance, HDR is likely to be very inefficient. As 
the HRT would require mutations within the seed region there was no known 
disadvantage to choosing the closest possible PAM to the target site – a TGG sequence 
starting within codon 337 at position c1010. Following identification of this PAM, a 
20bp sequence upstream (5’-ACAGAGCAGTTGGGGTATGA-3’) was screened 
(crRNA-1) to identify potential off-target effects using the Zhang lab online CRISPR 
design tool (http://crispr.mit.edu/). The ten highest scoring off-target sites are shown 
in Table 23. 
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Score Mismatches UCSC gene Locus 
31.5 1MMs [19]   chr8:-64049192 
2.3 3MMs [2:3:5]  chr12:-131021031  
1.5 3MMs [3:4:9]   chr1:-177306588 
1.2 3MMs [1:10:17]   chr18:-74392586  
1.1 3MMs [1:5:19]  chr12:-125358101 
0.6 4MMs [2:3:10:20]  chr3:+124103400 
0.6 3MMs [1:10:18]  chr8:-93078163 
0.6  4MMs [1:7:8:9]  chr5:+31676555 
0.6 4MMs [1:5:10:17 NM_001406 chr17:-7612097 
0.5 3MMs [3:17:20]  chr4:+176460365 
Table 23: Ten highest off-target site scores for sgRNA-1. 
Given the lack of affinity for crRNA-1 for most other genomic targets with no protein-
coding genes affected with less than four mismatches, the sequence appears a good 
candidate. Had off-target scores been higher, a dual nickase strategy could have been 
considered. Shifting the sgRNA upstream just one basepair resulted in a markedly 
less favourable off target screen (data not shown).   
 
With a theoretically acceptable crRNA, consideration was then given to the design of 
the HRT. An HRT with 40bp homology arms flanking the target nucleotide at position 
1009 was designed (Table 24).  






Table 24: Table showing the endogenous M337V and HRT sequences. Codon 337 
is denoted by bold black. Position 1009 is underlined. The PAM is highlighted yellow. 
The seed is highlighted in blue. Silent mutations are shown in bold red. The silent 
mutation responsible for the generation of a PspFI RE digest site is shown in lower 
case red with the cut site itself denoted by ‘|’. 
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Three silent mutations shown in red in Figure 24 have been introduced with the HRT 
in the gRNA binding sequence in addition to the A → G correction in position c1009. 
Of the silent mutations, T → C at position c998 creates a PspFI cut site. The recognition 
sequence of these restriction enzymes is shown in Figure 31. 
 
Figure 31: Diagram showing the recognition sequence of the PspFI restriction 
enzymes. Arrows denote the cut site which produces a sticky end with a 3bp 
overhang.  
 
Introduction of PspFI restriction site is ideal since within the exon 6 PCR amplicon 
this enzyme will only cut once within lines in which HDR has successfully occurred 
and produces fragments with over a 100bp difference in size which will be easy to 
detect via gel electrophoresis during the screening stage. 
In this case, the repair template can be obtained relatively cheaply from industry 
suppliers (Sigma Aldrich or IDT as just two examples). This is because constructs are 
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Using the same resource from Sigma-Aldrich used to design primers earlier in this 
thesis the HDR template can be synthesised. The following information is required: 
 
Parameter Options 











Solution (in water) 
Solution (in TE) 
Solution (in TRIS) 
Table 25: Table showing decisions required for the ordering of the HRT from 
Sigma-Aldrich. 
 
The Liu protocol recommends 15μg of Cas9 protein be incubated with 7.5-10ug of 
sgRNA at room temperature for 10 minutes to allow the formation of 
ribonucleoproteins (RNPs). This represents a very similar volume of Cas9 protein 
(16μg) recommended in a white paper by Lonza who use 200pmol sgRNA 
(Sentmanat and Miller)A. Transfection efficiency is reported to decrease if the volume 
of RNP solution exceeds 10% of the transfection volume. 
 
Consideration is now given to the manner in which these constructs will be delivered. 
Cas9 protein will be used instead of a Cas9 encoding plasmid for the advantages 
described in methods. The ssODN repair template can be transfected directly as 
oligonucleotides. The crRNA and tracrRNA can be ordered directly relatively 
inexpensively for industrial suppliers such as Integrated DNA Technologies. The 
necessary scaffold is automatically added to the crRNA sequence with this approach 
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and this strategy is cost efficient for labs in which editing is infrequent. These 
companies also provide protocols describing the assembly of ribonucleoprotein 
(RNP) complexes before transfection. 
 
Transfection and Determination of Cutting Efficiency 
 
Constructs can be introduced into target cells in a number of ways. Electroporation 
and lipofection are commonly usedB. I would attempt electroporation first for several 
reasons, all anecdotal. Firstly, I have some experience of electroporation following 
nucleofection of iPSCs in a BAC-transposon system. Secondly, previous success has 
been had by the Chandran lab on iPSCs using the CA137 protocol of the Lonza 4D-
Nucleofector and discussion at the Inaugural MRC Stem Cell Partnership Workshop 
in Edinburgh (06/06/2017-07/04/2017) confirmed that other groups were not only 
using the Lonza 4D-Nucleofector but also the very same protocol. Thirdly, a 
representative from Merck themselves at the Edinburgh University CRISPR/Cas9 
Workshop (16/05/2017) confirmed that they use Lonza’s (a competitor company) 
transfection systems for gene editing experiments. While there is a paucity of quality 
evidence for the advantages of electroporation over lipofection it is important to 
acknowledge that wisdom from those in the field is valuable and provides the 
potential to save time and money. 
 
The nucleofection of human embryonic stem cells (hESCs) has been recently 
described by Liu et al. (Liu et al. 2015). Following dissociation into single cells using 
a procedure identical to that that used at the start of the sMN generation protocol 
described in Methods. It is recommended by Liu that mTeSR1 medium is added to 
cells to stop the accutase digestion but previous success in our lab has not found this 
necessary. It is noted though that in the case of a cell line in which a large degree of 
cell death during transfection occurs this presents a modifiable step which may 
improve survival.  Addition of the ssODN repair template to this mixture is also 
107 | P a g e  
 
MScR The University of Edinburgh 2017 
required and concentrations used in the published literature vary at least from 0.5 – 
10μM for each microliter of nucleofection reaction mix volume.  
 
Following transfection, iPSCs should be plated at a density of 200,000 cells/well in a 
MG coated six-well plate in E8 MediaC. The E8 media should be supplemented with 
10μM Rock Inhibitor.  
 
Incubation at 37°C for several days allows recovery and upon reaching approximately 
80% confluence cells are dissociated with accutase and plated at a low density (~5000 
cells/10cm dish) to facilitate the picking of clonesD,E. Before clonal colonies are picked 
it is advisory to make some assessment as to the CRISPR-Cas9 activity and targeting 
efficiency of the RNP complex. CRISPR-Cas9 activity can be assessed by T7 
endonuclease assay on leftover transfected cells following the platedown to 10cm 
dishes. In brief, the T7 endonuclease assay is based on the principle that T7 
endonuclease specifically cleaves the heteroduplex DNA structures.  DNA should be 
extracted from transfected cells and exon 6 amplified using previously described 
protocols (see Methods). The PCR amplicon is denatured and re-annealed resulting in 
the formation of heteroduplex structures if mutations are introduced due to the error-
prone NHEJ after Cas9 nuclease activity. Sites of mutagenesis are cleaved by T7 
endonuclease producing a banding pattern that can be resolved by agarose gel 
electrophoresis. In this case, in addition to the 452bp PCR amplicon, two large bands 
of ~290 and ~165bp would be expected with a number of much smaller cleavage 
products. If this banding pattern is not observed, it is likely the RNP complex has 
poor cutting efficiency and continuation with clonal screening is likely to fail. A new 
RNP should be designed or transfection parameters optimised.  
 
Even though the efficiency is observed to be < 15 % it is encouraged to check if the 
HDR per-se is successful by performing PspF1 RFLP analysis on the transfected cells 
prior to colonies are picked. An additional band at ~288bp, if observed, indicates 
successful gene targeting.  
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Clonal Selection and Screening 
 
Assuming a positive T7 endonuclease activity and PspF1 RFLP results, the clonal 
colonies are picked using pipette tips and a microscope in sterile conditions. Previous 
work in the lab suggests around 500 clones should be picked but it is acknowledged 
that this efficiency varies from experiment to experiment. Clonal colonies are plated 
in individual wells of a MG-coated 96-well plate and grown in E8 (Essential 8™ 
Medium, ThermoFisher Scientific, A1517001) with RI. Following further culture for 
several days in these plates cells should be passaged with 0.5mM EDTA to generate 
at least two replicates of each plate. One of these will be subject to RFLP screening 
and the other maintained in culture so that candidate clones with promising RFLP 
results can be selected. 
 
Remaining cells should be subject to RFLP analysis with PspFI to determine if 
transfection has been successful. It should be noted that the primers used to generate 
the amplicon subject to RFLP must lie out with the HRT as is the case here. Failure to 
recognise this can result in amplification of the repair template itself and/or random 
targeting events leading to false-positive screening. Successful HDR targeting can be 
either be mono-allelic or bi-allelic, RFLP analysis with PspF1 will be able to determine 
both the scenarios. Clones with mono-allelic targeting will have ~450bp, 288bp and 
165bp bands whereas clones with bi-allelic targeting event will only have 288bp and 
165bp band in on an agarose gel. If RFLP analysis with PspFI does not demonstrate 
the expected dual banding pattern (~288bp and ~165bp) the transfection is highly 
unlikely to have been successful and transfection should be reattempted with altered 
parameters. 
 
In clones with promising RFLP results sequencing of exon 6 can then be undertaken 
to confirm whether gene correction (pM337M) has been successful. In case of clones 
with a mono-allelic targeting event, it is important to sequence both the alleles using 
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TA cloning to confirm the untargeted allele has not acquired other mutations due to 
the Cas9 nuclease activity.  
 
Searching for Off-Target Effects 
 
Attempts should then be made to identify off-target effects. One approach is via 
whole genome sequencing (WGS) though this is time-consuming, expensive and 
coverage may be a concern. An alternative approach is selectively sequencing 
genomic regions in which off-target cuts might be expected using bioinformatics 
techniques such as that described above by the Zhang lab. WGS has the added 
advantaged of detecting not only CRISPR-Cas9 off-target effects but also other 
sporadic mutations which may have occurred throughout the gene editing process.  
 
It may be advisable to also culture non-edited clones that have been subject to the 
entire CRISPR-Cas9 gene editing process. It has been argued that such cell lines may 
provide a more appropriate control than the original parent line. In reality, 
information is likely to be gained from a comparison between all lines available. 
 
 
Chapter 5: Correction of the TARDBPM337V Mutations Notes 
 
A – Not peer reviewed. 
B – Within the field there is anecdotal evidence that lipofection has poor efficiency 
for motor neuron transfection (though here iPSCs are transfected). 
C – MG is not the only option here and we have also assessed the survival of post-
electroporation iPSCs on laminin 521. In my hand's survival is better on MG-coated 
plates though in difficult to transfect lines alternative approaches could be tried. 
D – Accutase is used rather than trypsin or collagenase to yield single cells allowing 
truly clonal colony selection. 
E – I have had some experience picking clones during the generation of C9-Δ3. 
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Supplemental Figures 
 
Supplemental Figure 1: HSP90B1 transcript levels in three-week-old sMNs are 
increased in C9-3 but consistent between other lines examined. Expression fold 
change of HSP90B1 transcript in control (green), C9ORF72 mutant (red) and gene-
edited (blue) MN RNA. Each point represents the mean of three technical replicates 
from RNA samples from independent sMN conversions. Black bars mark the mean. 
Error bars show the 95% CI. Kruskal-Wallis refuted the null hypothesis with 
(p=0.0151). Dunn’s multiple comparisons test was performed and results are shown 
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Supplemental Figure 2: Without outlier exclusion, significant upregulation of 
HSPB8 was observed only in C9-3. Expression fold change of HSPB8 transcript in 
control (green), C9ORF72 mutant (red) and gene-edited (blue) MN RNA. Each point 
represents the mean of three technical replicates from RNA samples from 
independent sMN conversions. Black bars mark the mean. Error bars show the 95% 
CI. Kruskal-Wallis refuted the null hypothesis with (p=0.0364). Dunn’s multiple 
comparisons test was performed and results are shown in Supplemental Table 5.   
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Supplemental Figure 3: XPO1 transcript is not differentially expressed among 
control, C9ORF72 mutant and gene corrected lines. Expression fold change of XPO1 
transcript in control (green), C9ORF72 mutant (red) and gene-edited (blue) MN RNA. 
Each point represents the mean of three technical replicates from RNA samples from 
independent sMN conversions. Black bars mark the mean. Error bars show the 95% 
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Supplemental Figure 5: Plot showing that mean normalised integrated density 
(mnID) does not decrease significantly with increasing doses of DMSO up to 
10gL/mL. Each point denotes the mnID for one well. The colour of data points 
corresponds to genotype: green = control, red = mutant and blue = gene corrected. 
Data is clustered by platedown (dimension not displayed) which has been accounted 
for in the subsequent statistical analysis. 
 
 
The effect of DMSO on cell survival up to the highest concentration used (0.1%) was 
investigated this time using mnID as a survival surrogate. The mean normalised 
integrated density (mnID) (a surrogate for viability) at 48h was investigated as the 
independent variable and its relationship with increasing volumes of DMSO is shown 
below. A volume of 10μL DMSO corresponds to 0.1% DMSO – the highest dose used 
in any experiment. The results of the likelihood ratio test are shown in Supplemental 
Table 6. 
 
Supplemental Figure 5 suggests that increasing doses of DMSO are not associated 
with decreased sMN viability as determined by mnID and this is reflected in the 
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Supplemental Figure 6: GA and GP DPR protein aggregates are present at higher 
levels in a C9ORF72 mutant line relative to control lines in three-week-old sMN 
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Supplemental Tables 
 
Supplemental Table 1: Non-protein coding RNAseq hits not subject to GO 
analysis. 
 
Non-Protein Coding RNAseq hits 














 RP11-83N9.5  
 
Supplemental Table 2: Delta-delta Ct values for all qPCR replicates with outliers 
removed. 
 
Delta-delta Ct values for data in which outliers have been removed 
Transcript Cell line Replicate 1 Replicate 2 Replicate 3 Replicate 4 
HSP90B1 Con2 0 0 0 0 
Con1 1.236306 0.319898 -0.195069072 1.04324 
C9-1 NA 0.35825 -0.2888794944351  0.027117 
C9-3 NA -0.72484 -0.862288496 -0.62477 
C9-Δ 0.990026 0.169191 -0.35358019 2.60853 
HSPB8 Con2 0 0 0 0 
Con1 2.056279 1.960721 2.856852395 2.135936 
C9-1 -2.04378 -1.87567 -1.271945704 -0.49843 
C9-3 -3.00577 -1.41333 -0.971130567 -1.01401 
C9-Δ1 -1.46253 NA 0.584017102 0.925905 
XPO1 Con2 0 0 0 0 
Con1 -0.38903 0.875346 -0.131471104 0.08098 
C9-1 -0.44948 0.026703 -0.771250647 -0.18782 
C9-2 -0.31302 NA 0.264785287 0.531315 
C9-Δ1 -0.08703 NA -0.044589753 0.231451 
Number of outliers 
removed 
8 12 0 5 
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Supplemental Table 3: Delta-delta Ct values for all qPCR replicates. 
 
Delta-delta Ct values for all data 
Transcript Cell line Replicate 1 Replicate 2 Replicate 3 Replicate 4 
HSP90B1 Con2 0 0 0 0 
Con1 1.236306 0.319898 -0.195069072 1.661096 
C9-1 0.200944 0.35825 -
0.2888794944351  
0.910776 
C9-3 -1.54676 -0.72484 -0.862288496 -0.62477 
C9-Δ1 0.990026 0.169191 -0.35358019 1.951242 
HSPB8 Con2 0 0 0 0 
Con1 1.615841 4.800074 2.856852395 2.135936 
C9-1 -2.04378 0.829417 -1.271945704 -0.49843 
C9-3 -3.00577 -0.64785 -0.971130567 -1.45578 
C9-Δ1 -1.46253 -1.95477 0.584017102 2.603072 
XPO1 Con2 0 0 0 0 
Con1 -0.38903 5.163168 -0.131471104 0.08098 
C9-1 0.179312 2.417937 -0.771250647 -0.18782 










Supplemental Table 4: Results from Dunn’s multiple comparisons testing post- 
Kruskal-Wallis test on HSP90B1 qPCR ΔΔCt values with outliers not removed. 
Interpretation of HSP90B1 transcript expression does therefore not vary with outlier 
removal. In both cases a statistically significant (α = 0.05) upregulation was observed 
in C9-2 only. 
 
Comparison P value 
Con1 vs. C9-1 >0.9999 
Con1 vs. C9-3 0.0225 
Con1 vs. C9-Δ1 >0.9999 
 
Supplemental Table 5: Results from Dunn’s multiple comparisons testing post- 
Kruskal-Wallis test on HSPB8 qPCR ΔΔCt values with outliers not removed. 
Interpretation of HSPB8 transcript expression varies outlier removal. Without outlier 
removal, a significant upregulation of HSPB8 is observed in C9-2 only. 
 
Comparison P value 
Con1 vs. C9-1 0.1128 
Con1 vs. C9-3 0.0280 
Con1 vs. C9-Δ1 0.1901 
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Supplemental Table 6: Output from a mixed linear regression model and 
likelihood ratio test investigating the relationship between 48 mnID with dose and 
genotype as fixed effects and platedown modelled as a random effect. Construction 
of a model testing the null hypothesis allowed calculation of the likelihood ratio test 
p value which rejects the null hypothesis that DMSO does influences viability as 




Coefficient Standard Error T value Likelihood 
ratio test 
48h mnID -0.297 4.81840 0.092 P = 0.9266 
 
 
